


SUBSTITUTED 1,3-BENZODIOXOLES


This invention relates to novel substituted 1,3-benzodioxole compounds which have antidiabetic, antihyperglycemic, and antiobesity properties. The present invention also relates to pharmaceutical compositions containing these compounds, methods for the preparation of these compounds, and methods for the use of these compounds in treating diabetes and/or hyperglycemia and/or obesity in mammals.

BACKGROUND OF THE INVENTION

Bloom, et al., U.S. Patent 5,061,727, disclose substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles of general formula (I)



wherein R₁ and R₄ may be one or more groups which may be the same or different and are selected from the group consisting of hydrogen, C₁ to C₄ alkyl, C₁ to C₄ alkoxy, hydroxy, halogen, trifluoromethyl, carboxy, hydroxyalkyl, alkoxycarbonyl, C₁ to C₄ thioalkyl, sulfonyl and sulfinyl; X is a divalent radical consisting of



wherein R' is selected from the group consisting of hydrogen, C₁ to C₄ alkyl and C₁ to C₄ acyl and Y is selected from the group consisting of carbonyl and thiocarbonyl; R₂ and R₃ may be the same or different and are selected from the group consisting of hydrogen and C₁ to C₄ alkyl; R₅ and R₆ are selected from the group consisting of hydrogen, carboxy, alkoxycarbonyl, hydroxymethyl, -CH₂OCH₂COOR₇ and -CH₂OCH₂CH₂OR₇, where R₇ is hydrogen or C₁ to C₄ alkyl; with the provision that R₅ and R₆ may not both be hydrogen; which have antihyperglycemic and antiobesity activity.

- 2 -

The synthesis, antidiabetic effects, and antiobesity effects of (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (which is one of the compounds disclosed by Bloom, et al. in U.S. Patent 5,061,727) are detailed in Bloom, et al. *J. Med. Chem.*, 1992, 35, 3081, Largis, et al. *Drug Dev. Res.*, 1994, 32, 69, and Bloom, et al. *Drugs of the Future*, 1994, 19, 23.


The compounds of the present invention possess greatly increased potency at human β_3 receptors in comparison to the compounds in Bloom, et al., U.S. Patent 5,061,727. They retain high selectivity for the β_3 receptor and show much higher antiobesity and antihyperglycemic activity in animal models than the compounds of the prior art. The compounds have intrinsic activity at human β_3 receptors and can directly bring about antihyperglycemic and antiobesity effects, but may also be hydrolyzed in vivo to deliver a compound of the type disclosed in Bloom, et al., U.S. Patent 5,061,727 where R₅ and R₆ are carboxy. Thus the compounds may act as prodrugs. Therefore, the compounds of this invention are useful in treating diabetes, hyperglycemia, and obesity, exhibiting minimal side effects such as heart rate increase and muscle tremor in humans and animals, when formulated into pharmaceutical compositions.

DESCRIPTION OF THE INVENTION

The compounds of the present invention achieve their antidiabetic, antihyperglycemic, and antiobesity effects by acting as selective agonists at β_3 adrenergic receptors. The stimulation of these receptors on white and brown adipocytes promotes both lipolysis (breakdown of fat) and energy expenditure. Selective stimulation of β_3 adrenergic receptors is important for chronic treatment. Stimulation of other β -receptors could cause side effects such as increased heart rate (β_1 effect) and muscle tremor (β_2 effect). The compounds of the present invention show high selectivity for β_3 adrenergic receptors.


According to the present invention there are provided new compounds of the formula (II):

- 3 -



wherein:

- 5 R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen;
 R₂ is hydrogen or C₁ to C₆ trialkylsilyl;
 R₃ is hydrogen or C₁ to C₆ alkoxycarbonyl;
 or R₂ and R₃ are joined to form a ring:



10

wherein R' is hydrogen, C₁ to C₆ alkyl, or aryl;

- R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl;
 R₇ and R₈ are independently OR₉ or NR₁₀R₁₁;
 15 R₉ is hydrogen, C₁ to C₁₂ alkyl, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision that R₉ is not hydrogen in both R₇ and R₈;
 R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, arylalkyl, aryl,
 20 furanylalkyl, or alkoxycarbonylalkyl;
 R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl;
 and the pharmaceutically acceptable salts thereof, the enantiomers thereof, the racemic mixtures thereof, and the diastereomeric mixtures thereof.

- 25 In the description above, aryl may be phenyl or naphthyl; arylalkyl may be phenyl C₁ to C₆ alkyl or naphthyl C₁ to C₆ alkyl; alkoxy alkyl may be C₁ to C₆ alkoxy C₁ to C₆ alkyl; and heteroaryl may be pyridyl, thiophenyl, furanyl, imidazolyl, oxazolyl, or thiazolyl. The aryl, arylalkyl and heteroaryl groups referred to above may

- 4 -


be optionally substituted with one or more moieties selected from halogens, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -CN, or -OH groups. In a more preferred embodiment of this invention, the phenyl C₁ to C₆ alkyl group may be optionally substituted by one or more substituents selected from F, Cl, Br, CH₃ or CF₃.

5

This invention also provides processes for preparing the compounds of the invention which comprise one of the following:

a) reacting a compound of formula:

10



wherein R₂ - R₆ are as defined above and R₈' is OAg or R₈ as defined above excepting OH with a compound of formula:

15




wherein R₁₂ and R₁₃ are as defined above to give a compound of formula II wherein R₉ is

20




or b) reacting a compound of formula:



25 wherein R₁-R₆ and R₈ are as defined above with compound of formula R₉OH where R₉ is as defined above excepting hydrogen to give a corresponding compound of formula II;

- 5 -

or c) hydrolysing a compound for formula:




- 5 wherein R_1 , R_4 , R_5 , R_6 , R_7 and R_8 are as defined above and R_2 is trialkylsilyl and R_3 is $(C_1-C_6 \text{ alkoxy})\text{carbonyl}$ to give a corresponding compound of formula 1 wherein R_2 and R_3 are both hydrogen,


- 10 or d) reacting a compound of formula II wherein R_2 and R_3 are both hydrogen with an aldehyde of formula:



- 15 wherein R' is as defined above to give a corresponding compound of formula I wherein R_2 and R_3 are joined to form a ring:



- 20 or e) reacting a compound of formula:



- 6 -

wherein R_1 , R_4 , R_5 and R_8 are as defined above with the proviso neither R_2 or R_3 is hydrogen with a compound of formula:


$Z-R_9$

5

wherein Z is Cl , Br , I , methanesulfonate or p -toluenesulfonate and R_9 is as defined in above excepting hydrogen, to give a corresponding compound of formula II;

or f) hydrolysing a compound of formula:


10



wherein R_1 , R_2 , R_3 , R_4 , R_5 and R_6 are as defined in Claim 1, R_8 is OR_9' or $NR_{10}R_{11}$ and R_9' is C_1 - C_{12} alkyl, C_1 - C_{12} cycloalkyl, C_1 - C_{12} silylalkyl, aryl,


15

arylalkyl, alkoxyalkyl or heteroaryl to give a compound of formula:




20

wherein R_1 - R_6 and R_8 are as defined above providing that R_2 and R_3 are both hydrogen or joined to form a ring:




or g) reacting a compound of formula:


- 7 -



wherein R_1 - R_6 and R_8 are as defined above and R_9 is as defined above, with a
 5 compound of formula:



wherein R_{11} and R_{12} are as defined above to give a compound of formula:



wherein R_1 - R_6 , R_8 , R_{11} and R_{12} are as defined above.

15 The most preferred compounds of this invention are the following and the pharmaceutically acceptable salts thereof:

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methoxy-ethyl) ester;

20 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diphenethyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-butoxy-ethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-phenoxy-ethyl) ester;

25 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-ethoxy-ethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-tert-butoxy-ethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-tert-butoxy-ethyl) ester;

5 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isobutoxy-ethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzyl) ester;

10 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclohexyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclopentyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dioctyl ester;

15 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dipentyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dihexyl ester;

20 carbonic acid 3-chloro-benzyl ester 2-(3-chloro-benzyloxycarbonyloxy)-4-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-phenyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-phenyl-ethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diheptyl ester;

25 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dinonyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-decyl ester;

30 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid didodecyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isopropoxy-ethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid isopropyl ester;

- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid ethyl ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-methoxycarbonylmethyl ester;
- 5 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propoxycarbonylmethyl ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methoxycarbonyl-ethyl) ester;
- 10 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropoxycarbonylmethyl ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethoxycarbonylmethyl ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-ethoxycarbonyl-ethyl) ester;
- 15 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-trimethylsilanylmethyl ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-trimethylsilanyl-ethyl) ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-trimethylsilanyl-propyl) ester;
- 20 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3,3-dimethyl-butyl) ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclohexylmethyl ester;
- 25 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-methyl-pentyl) ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclohexyl-ethyl) ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propyl) ester;
- 30 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclopropylmethyl ester;
- 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclopropylmethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclobutylmethyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclopentyl-ethyl) ester;

5 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-acetoxymethyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propionyloxymethyl ester;

10 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-butyryloxymethyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isobutyryloxymethyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-heptanoyloxymethyl ester;

15 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-methyl-pentanoyloxymethyl) ester ;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-hexanoyloxymethyl ester;

20 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis- (2,2-dimethyl-propionyloxymethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis cyclohexanecarbonyloxymethyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-propionyloxy-ethyl) ester;

25 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(2,2-dimethyl-propionyloxy-ethyl) ester];

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3,3-dimethyl-butyryloxymethyl) ester;

30 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(3,3-dimethyl-butyryloxy)-ethyl] ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propionyloxymethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl} benzo[1,3]dioxole-2,2-dicarboxylic acid bis-benzoyloxymethyl ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzoyloxy-ethyl) ester;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-butyryloxymethyl) ester;

5 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-amide;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-2-propyl amide;

10 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-n-butyl amide;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-phenylmethyl amide;

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-furanylmethyl) amide;

15 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(glycine ethyl ester) amide;

5-{2-[2-(3-chloro-phenyl)-3-oxazolidinyl]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid;

20 Also according to the present invention there is provided a method of treating diabetes and/or hyperglycemia and/or obesity in humans or other mammals which comprises administering to a human or other mammal an antiobesity effective amount or an antihyperglycemia effective amount of a compound of the present invention.

25 It is understood that the effective dosage of the active compounds of this invention may vary depending upon the particular compound utilized, the mode of administration, the condition, and severity thereof, of the condition being treated, as well as the various physical factors related to the individual being treated. For treating diabetes mellitus and/or hyperglycemia generally satisfactory results may be obtained
30 when the compounds of this invention are administered to the individual in need at a daily dosage of from about 0.1 mg to about 1 mg per kilogram of body weight, preferably administered in divided doses two to six times per day, or in a sustained release form. For most large mammals, the total daily dosage is from about 3.5 mg to about 140 mg. This regimen may be adjusted to provide the optimal therapeutic
35 response.

- 12 -

When treating obesity, in conjunction with diabetes and/or hyperglycemia, or alone, generally satisfactory results can be obtained when the compounds of this invention are administered at a daily dosage of from about 0.1 mg to about 1 mg per kg of body weight, preferably given in divided doses two to six times per day or in a sustained release form. For most large mammals, the total daily dosage is from about 3.5 to about 140 mg, preferably from about 3.5 to about 5 mg. In the case of a 70 kg human adult, the total daily dose will generally be from about 7 mg to about 70 mg and may be adjusted to provide the optimal therapeutic result.

The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredients, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

These active compounds may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, there preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol,

- 13 -

propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

5 The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving lean meat to fat ratio in edible animals, i.e. ungulate animals and poultry.

10 Animal feed compositions effective for increasing lean meat deposition and for improving lean meat to fat ratio in poultry, swine, sheep, goats, domestic pets and cattle are generally prepared by mixing the compounds of the present invention with a sufficient amount of animal feed to provide from about 1 to 1000 ppm of the compound in the feed. Animal feed supplements can be prepared by admixing about 75% to 95% by weight of a compound of the present invention with about 5% to about 25% by weight of a suitable carrier or diluent. Carriers suitable for use to make up the feed
15 supplement compositions include the following: alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, sodium chloride, cornmeal, cane molasses, urea, bone meal, corncob meal and the like. The carrier promotes a uniform distribution of the active ingredients in the finished feed into which the supplement is blended. It thus performs an important function by ensuring proper distribution of the active ingredient
20 throughout the feed. The supplement is used as a top dressing for the feed, it likewise helps to ensure uniformity of distribution of the active material across the top of the dressed feed.

25 The preferred medicated swine, cattle, sheep and goat feed generally contain from 0.01 to 400 grams of active ingredient per ton of feed, the optimum amount for these animals usually being about 50 to 300 grams per ton of feed. The preferred poultry and domestic pet feed usually contain about 0.01 to 400 grams and preferably 10 to 400 grams of active ingredient per ton of feed.

30 For parenteral administration the compounds of the present invention may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal in which increase in lean meat deposition and improvement in lean mean to fat ratio is sought. In general, parenteral administration involves injection of a sufficient amount of the compounds of the present invention to
35 provide the animal with 0.001 to 100 mg/kg/day of body weight of the active

- 14 -

ingredient. The preferred dosage for swine, cattle, sheep and goats is in the range of from 0.001 to 50 mg/kg/day of body weight of active ingredient; whereas, the preferred dose level for poultry and domestic pets is usually in the range of from 0.001 to 35 mg/kg/day of body weight.

5

Paste formulations can be prepared by dispersing the active compounds in a pharmaceutically acceptable oil such as peanut oil, sesame oil, corn oil or the like. Pellets containing an effective amount of the compounds of the present invention can be prepared by admixing the compounds of the present invention with a diluent such as
10 carbowax, carnuba wax, and the like, and a lubricant, such as magnesium or calcium stearate, can be added to improve the pelleting process. It is, of course, recognized that more than one pellet may be administered to an animal to achieve the desired dose level which will provide the increase in lean meat deposition and improvement in lean meat to fat ratio desired. Moreover, it has been found that implants may also be made
15 periodically during the animal treatment period in order to maintain the proper drug level in the animal's body. The method of the present invention has several advantages; for the pet owner or veterinarian who wishes to increase leanness and trim unwanted fat from pet animals, the present invention provides the means by which this can be accomplished. For the poultry and swine raisers, using the method of the present
20 invention yields leaner animals which command higher prices from the meat industry.

Further, according to the present invention there are provided pharmaceutical compositions of matter comprising an effective amount of the compounds of the present invention in combination with a pharmaceutically acceptable carrier; as well as a method
25 for increasing the content of lean meat in edible animals, which comprises administering to edible mammals an effective amount of the compound.

Also according to the present invention there are provided processes for producing the compounds of the present invention.

30

PROCESS OF THE INVENTION


The compounds of the present invention may be prepared according to one of the general processes outlined below.

35

- 15 -


As outlined in Scheme I, a disodium carboxylate **1** is converted to a disilver carboxylate and treated with an iodo derivative **2** to yield the diester compounds **3** wherein R_1 , R_4 , R_5 , R_6 , R_{12} , and R_{13} are as defined above.

5 Scheme I



Alternatively, a dicarboxylic acid **4** (Scheme II) is treated with an alcohol R_9OH and an acid catalyst to yield the diester compounds **5** wherein R_1 , R_4 , R_5 , R_6 , and R_9 are as defined above.


Scheme II



- 16 -

As outlined in Scheme III, the diester compounds 5 can also be produced by protecting the hydroxy and amino groups of compound 6 with R₂ and R₃ groups, respectively, basic hydrolysis of the ethyl esters, alkylation of the carboxyl groups of compound 7 with an alkylating agent Z-R₉, and removing the protecting groups R₂ and R₃, wherein R₁, R₂, R₃, R₄, R₅, R₆, and R₉ are as defined above and Z is Cl, Br, I, methanesulfonate, trifluoromethanesulfonate, or para-toluenesulfonate.


Scheme III



As outlined in Scheme IV, a dicarboxylate 1 is treated with an aldehyde R'CHO to yield the oxazoline compounds 8, wherein R₁, R₄, R₅, R₆, and R' are as defined above.

- 17 -

Scheme IV




5

As outlined in Scheme V the diester compounds **5** can be hydrolyzed under basic conditions to a monoester **9a** and/or **9b**, wherein R_1 , R_4 , R_5 , R_6 , and R_9 are as defined above. One or both of the diastereomers **9a** and **9b** may be produced in the hydrolysis reaction.

10


Scheme V



- 18 -

As illustrate in Scheme VI, a diester compound 5 is reacted with an amine $\text{HNR}_{11}\text{R}_{12}$ to yield the diamide compounds 10, wherein R_1 , R_4 , R_5 , R_6 , R_9 , R_{11} , and R_{12} are as defined above.

5 Scheme VI



10 The compounds of this invention were tested for antihyperglycemic and antiobesity activity according to the following procedures.

Human Beta Adrenergic Receptor Selectivity

15 The activity of the test compounds on human β -adrenergic receptors was determined with Chinese hamster ovary (CHO) cells transfected with human β_2 , or β_1 adrenergic receptors. Agonist activity is indicated by increased cAMP levels in the CHO cells. Selectivity of the test compounds for the β_3 receptor was assessed by comparison with results in β_2 and β_1 adrenergic receptor transfected cells.

20

Procedure:

- 1). Chinese hamster ovary (CHO) cells transfected with human β_2 , or β_1 adrenergic receptors were used in the assay.
- 25 2). Cells were grown to confluent conditions in 24 well plates.

- 19 -

- 3). Drugs were dissolved in DMSO at a concentration of 10 μ M.
- 4). Cells were incubated with drug at 10 nM concentration for 10 min at 37° C. Isoproterenol (Standard 1) was used as the standard compound and assayed at 10 μ M which gives a maximal cAMP elevation in all 3 cell types.
- 5). Cell cAMP concentrations were assayed using a scintillation proximity assay kit from Amersham Corp., Chicago, IL.
- 6). Activities for the test compounds are expressed as a percentage of the isoproterenol response.

10 Production of the CHO cells transfected with human β_2 , or β_1 adrenergic receptors, and compound test procedures utilizing the CHO cells, are described by Emorine et al. in their article "*Molecular Characterization of the Human Beta3-Adrenergic Receptor*", Science 1989, 245(8), 1118-1121 and by Muzzin et al. in the article "*An Adipose Tissue-Specific Beta3-Adrenergic Receptor*", J. Biol. Chem.1991, 15 266, 24053-24058.

Effects on Free Fatty Acid Levels in Rats

20 Rats respond to a single oral dose of β_3 agonists by increasing plasma free fatty acids (FFA) in response to β_3 receptor stimulation on the plasma membrane of the fat cell. 5-(2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diisopropyl ester (Standard 2) was used as a standard compound. All test compounds were dosed at 0.1 mg/kg and compared to the response by Standard 2.

25

Procedure:

- 1). Drugs were dissolved in DMSO at 10 mg/ml.
- 2). Twenty μ l of the DMSO-drug solution was added to 10 mL methyl cellulose:tween-80 (0.5%:0.1%) for a final concentration of 20 μ g/mL.
- 3). Methyl cellulose:tween-80 drug suspension was given via gavage (1 mL/200g body weight; or 0.1 mg/kg) to rats and blood was collected 50 min later.
- 4). Plasma was analyzed for free fatty acids using a kit supplied by Biochemical Diagnostics Inc. (Brentwood, N.Y.).

- 20 -

5). Drug response was calculated from the formula below.

$$\% \text{ FFA Response} = \frac{\text{FFA (compound)} - \text{FFA vehicle}}{\text{FFA (Standard 2)} - \text{FFA vehicle}} \times 100$$

5

Effects on Hyperglycemia in Mice

On the morning of Day 1 (baseline), 35 mice (male, db/db (C57BL/KsJ), Jackson Laboratories, 2 to 7 months of age and 35 to 60 g) were fasted for 4 h, weighed, and a baseline blood sample was collected from the tail-tip of each mouse without anesthesia, placed directly into a fluoride-containing tube, mixed, and maintained on ice. Food was then returned to the mice. The plasma was separated and the levels of glucose in the plasma were determined by an Abbot VP Analyzer. Because of the variable plasma glucose levels of the db/db mice, the 5 mice having the most extreme (i.e., highest or lowest) plasma glucose levels were excluded and the remaining 30 mice were randomly assigned into 7 groups of equivalent mean plasma glucose level (vehicle control, ciglitazone (Standard 3), and 5 test compound groups). On the afternoon of Days 1, 2, and 3 the vehicle (0.2 mL of 2% Tween 80/saline w/v) or test compounds were administered (p.o.) to the ad libitum fed mice. On the morning of Day 4, the food was removed from the cages for 3 h, a blood sample was collected, and the mice were then given the fourth administration of test compound or vehicle. Additional blood samples were collected at 2 and 4 h after test compound administration. Plasma glucose levels were determined. To assess test compound activity, the percent change of an animal's plasma glucose level on Day 4 (mean of 2 and 4 h values) from its level before test compound administration (Day 1 baseline sample) was determined as follows:

$$\frac{\text{Mean of 2 and 4 h samples (Day 4)}}{\text{Baseline sample (Day 1)}} \times 100$$

30

A 50-60% reduction of plasma glucose levels in the hyperglycemic db/db mice represents a normalization of glucose levels.

Table I

Compound (Example)	β_1^a	β_2^a	Rat Free Fatty Acid ^b	db/db Mice Plasma Glucose ^c
1		4%	65%	
2		0.022 μ M	0.071 mg/kg	0.128 mg/kg
3		0%	20%	
4		1%	2%	
5		4%	115%	
6		3%	14%	
7		2%	22%	
8		1%	50%	
9		16%	22%	
10		0%	59%	
11		nt	118%	
12		1%	48%	
14		5%	65%	
15		18%	46%	
16		nt	0.128 mg/kg	
17		nt	nt	
18		6%	25%	
19		2%	36%	
20		0%	48%	
21		2%	0.086 mg/kg	
22		0.015 μ M	45%	
23		nt	57%	
24		nt	nt	
25		6%	30%	
26		7%	42%	
27		5%	78%	
28		2%	22%	
29		2%	9%	
30		0%	75%	
31		5%	0.090 mg/kg	
32		2%	33%	
33	5.90 μ M	0.100 μ M	0.080 mg/kg	0.201 mg/kg
34		2%	74%	
35		4%	69%	
36		2%	37%	
37		3%	33%	
38		0.274 μ M	0.086 mg/kg	
39		1%	71%	
40	8.4 μ M	0.420 μ M	0.071 mg/kg	
41		22%	36%	

Compound (Example)	β_1^a	β_2^a	Rat Free Fatty Acid ^b	db/db Mice Plasma Glucose ^c
42		0%	39%	
43		0%	10%	
44		0%	24%	
45		1%	26%	
46		16%	23%	
47		0%	37%	
48		4%	29%	
49		4%	50%	
50		0%	19%	
51		0%	2%	
52		2%	23%	
53		2%	20%	
54		7%	24%	
55		0%	31%	
56		8%	31%	
57		0%	30%	
58		8%	35%	
59		10%	17%	
60		3%	22%	
66		3%	40%	
68		5%	5%	
69		0.079 μ M	42%	
70	3.00 μ M	0.048 μ M	39%	
71		14%	0.076 mg/kg	
72		13%	43%	
73		0%	83%	
74		0%	86%	
75	5.4 μ M	0.058 μ M	0.026 mg/kg	0.110 mg/kg
76	0.980 μ M	0.074 μ M	42%	
77		5%	25%	
78	5.0 μ M	0.325 μ M	0.027 mg/kg	0.028 mg/kg
79		0%	61%	
80	2.4 μ M	0.055 μ M	81%	
81	0.380 μ M	0.059 μ M	61%	
82		nt	84%	
83		nt	13%	
84		nt	65%	
85		nt	60%	
86		nt	40%	

- 23 -

Compound (Example)	β_1^a	β_2^a	Rat Free Fatty Acid ^b	db/db Mice Plasma Glucose ^c
87		nt	68%	
89		nt	25%	
90		7%	11%	
91		7%	27%	
92		nt	40%	
93		nt	75%	
94		nt	78%	
95		0%	73%	
96		1%	71%	
97		4%	39%	
98		7%	86%	
99		16%	58%	
100		2%	10%	
101		3%	38%	
104		2%	83%	

^a Human β receptors expressed in Chinese hamster ovary cells, compounds tested at 10 nM, results expressed as % of isoproterenol activity (increase in cAMP) at 10 μ M.

5 ^b EC₅₀ (μ M) values determined for selected compounds.

^b Elevation of plasma free fatty acids in rats, compounds tested at 0.1 mg/kg, results expressed as % of 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]-dioxole-2,2-dicarboxylic acid diisopropyl ester response (78% increase) at 0.1 mg/kg. ED₅₀ (mg/kg) values determined for selected compounds.

10 ^c ED₅₀ (mg/kg/day) values for lowering of plasma glucose.

The following non-limiting specific examples further illustrate the present invention.

15

EXAMPLE 1

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methoxy-ethyl) ester hydrochloride salt

20

To a stirred mixture of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (1.0 g, 2.37 mmol), and 2-methoxy-

- 24 -

1-ethanol (10 mL) was added excess $\text{HCl}_{(g)}$. The mixture became homogeneous and was stirred at 23 °C. After 12 h, the solution was concentrated, and chromatographed on silica gel, eluting with $\text{CHCl}_3/\text{MeOH}$ (1/0, then 40/1, 20/1 and 10/1) to give fractions containing 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methoxy-ethyl) ester ($R_f=0.37$ (10/1 $\text{CHCl}_3/\text{MeOH}$)) as a viscous oil. This oil was dissolved in Et_2O (10 mL) and $\text{HCl}_{(g)}$ was bubbled through the solution for 1 min. The resulting solution was evaporated to give 1.06 g (78 %) of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methoxy-ethyl) ester hydrochloride salt as a white solid; ^1H NMR (300 MHz, CDCl_3): δ 1.33 (brm, 3H), 2.75-2.88 (brm, 1H), 3.10-3.30 (brm, 2H), 3.35 (s, 6H), 3.40-3.53 (brm 2H), 3.63-3.68 (complexm, 4H), 4.40-4.48 (brm, 4H), 5.40-5.50 (brd, 1H), 5.50-5.75 (brs, 1H), 6.70-6.91 (complex m, 4H), 7.18-7.38 (m, 2H), 7.43 (s, 1H), 8.60-8.85 (brs, 1H), 9.90-10.15 (brs, 1H); MS (ES) m/z (relative intensity): 538 (M^+-HCl , 100).

EXAMPLE 2

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diphenethyl ester hydrochloride salt

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-phenylethanol according to the procedure of Example 1 as a colorless oil; ^1H NMR (300 MHz; CDCl_3): δ 1.30-1.45 (brs, 3H), 2.80-2.90 (brm, 1H), 2.89 (t, $J = 6.9$ Hz, 4H), 3.10-3.30 (brm, 2H), 3.39-3.69 (brm, H), 4.40 (t, $J = 6.8$ Hz, 4H), 5.45-5.61 (brs, 2 H), 6.70-6.91 (brm, 3 H), 7.10-7.35 (complex m, 13H), 7.40-7.51 (brs, 1H), 8.60-8.85 (brs, 1H), 9.91-10.20 (brs, 1H); MS (ES) m/z (relative intensity): 630 (M^+-HCl , 40), 144 (100).

- 25 -

EXAMPLE 3

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-butoxy-ethyl) ester hydrochloride salt

5

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-butoxyethanol according to the procedure of Example 1 as a colorless oil; ¹H NMR (300 MHz, CDCl₃): δ 0.78-0.93 (m, 6H), 1.15-1.78 (m, 12H), 2.70-3.62 (brm, 5H), 3.31-3.47 (m, 4H), 3.57-3.73 (m, 4H), 4.29-4.53 (m, 4H), 5.47-5.57 (brs, 1H), 6.70-6.95 (m, 3H), 7.20-7.49 (m, 4H); MS (ES) *m/z* (relative intensity): 622 (M⁺-HCl, 20), 214 (10), 158 (10).

10

EXAMPLE 4

15 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-phenoxy-ethyl) ester hydrochloride salt

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-phenoxyethanol according to the procedure of Example 1 as an off-white gummy solid; ¹H NMR (300 MHz, CDCl₃): δ 1.23-1.40 (brs, 3H), 2.70-2.90 (brm, 1H), 3.05-3.30 (brm, 2H), 3.31-3.52 (brm, 2H), 4.12 (t, J = 4.4 Hz, 4 H), 4.57 (t, J = 4.8 Hz, 4 H), 5.38-5.60 (brs, 2H), 6.70-7.0 (complexm, 10H), 7.15-7.47 (complex m, 7 H), 8.60-8.80 (brs, 1H), 9.90-10.20 (brs, 1 H); MS (ES) *m/z* (relative intensity): 662 (M⁺-HCl, (100), 594 (20), 498 (35).

20

25

EXAMPLE 5

30 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-ethoxy-ethyl) ester hydrochloride salt

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-ethoxyethanol according to the procedure of Example 1 as an oily off-white gummy solid; ¹H NMR

35

- 26 -

(300 MHz, CDCl₃): δ 1.10-1.20 (t overlaps with d, J = 6.9 Hz, 9H), 1.31-1.41 (brm, 2 H), 2.75-2.90 (brm, 1H), 3.10-3.30 (brm, 2H), 3.50 (brq, J = 6.9 Hz, 4H), 3.62-3.71 (brm, 4H), 4.37-4.47 (brm, 4H), 5.30-5.70 (brm, 2H), 6.70-6.90 (brm, 4H), 7.19-7.50 (brm, 3H), 8.50-8.85 (brs, 1H), 9.90-10.30 (brs, 1H); MS (ES) m/z (relative intensity): 566 (M⁺-HCl, (60)).

EXAMPLE 6 and EXAMPLE 7

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-tert-butoxy-ethyl) ester
and

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-tert-butoxy-ethyl) ester

To a stirred mixture of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (1.0 g, 2.37 mmol), and 2-*t*-butoxy-1-ethanol (10 mL) was added *p*-toluenesulfonic acid (451 mg, 2.37 mmol). The mixture became homogeneous and was stirred at 23 °C. After 12 h, an additional portion of *p*-toluenesulfonic acid (351 mg, 1.84 mmol) was added. After a total of 90 h, the solution was concentrated, and chromatographed on silica gel, eluting with CHCl₃/MeOH (1/0, then 40/1, 20/1 and 10/1) to give 100 mg (7 %) of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-tert-butoxy-ethyl) ester (R_f =0.25 (10/1 CHCl₃/MeOH)) as a yellow oil and 320 mg (26 %) of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-tert-butoxy-ethyl) ester (R_f =0.09 (10/1 CHCl₃/MeOH)) as an off-white solid.

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-tert-butoxy-ethyl) ester; ¹H NMR (300 MHz, CDCl₃): δ 1.15 (d, 3H), 1.68 (s, 18 H), 1.85-2.40 (brm, 2H), 2.50-2.75 (m, 2H), 2.81-2.96 (m, 1H), 3.41-3.51 (m, 4H), 3.56-3.64 (m, 2H), 3.65-3.76 (m, 4H), 4.30-4.41 (m, 2H), 6.61-6.87 (m, 4H), 7.15-7.33 (m, 2H), 7.44 (s, 1H); MS (ES) m/z (relative intensity): 622 (M⁺, 90), 522 (M⁺-*t*-BuOCH₂CH₃, 60), 352 (40), 266 (100).

- 27 -

5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-tert-butoxy-ethyl) ester; ¹H NMR (300 MHz, CDCl₃): δ 1.10 (brm, 12H), 2.25-2.70 (brm, 2H), 3.00-3.30 (brm, 5H), 3.51-3.61 (m, 2H), 4.25-4.47 (m, 2H), 5.20-5.35 (brm, 1H), 6.50-6.70 (brm, 4H), 7.15-7.44 (m, 3H), 8.70-9.70 (brs, 1H). MS (ES) *m/z* (relative intensity): 522 (M⁺, 100).

EXAMPLE 8

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isobutoxy-ethyl) ester

10

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-isobutoxyethanol according to the procedure of Example 1 as a colorless oil; ¹H NMR (300 MHz, CDCl₃): δ 0.70-0.95 (m, 12H), 1.10-2.0 (complexm, 11H), 3.09-3.29 (m, 4H), 3.51-3.58 (m, 1H), 3.60-3.72 (m, 4H), 4.31-4.48 (m, 2H), 6.70-7.00 (m, 4H), 7.15-7.50 (m, 4H); MS (ES) *m/z* (relative intensity): 622 (M+HCl, 100).

15

EXAMPLE 9

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzyl) ester hydrochloride salt

20

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and benzyl alcohol according to the procedure of Example 1 as a gummy white solid: ¹H NMR (300 MHz, CDCl₃): δ 1.26-1.32 (m, 3H), 2.76 (brt, 1H), 3.01-3.21 (brm, 2H), 3.36-3.49 (brm, 2H), 5.24 (s, 4H), 5.41 (d, J=9.5 Hz, 1H), 6.70-6.88 (m, 3H), 7.12-7.44 (complex m, 14H), 8.70-8.83 (brs, 1H), 9.95-10.10 (brs, 1H); MS (ES) *m/z* (relative intensity): 602 (M⁺, 100).

25

30

EXAMPLE 10**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclohexyl) ester
hydrochloride salt**

5 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclohexanol according to the procedure of Example 1 as a yellow gum: ¹H NMR (300 MHz, CDCl₃): δ 1.10-1.40 (complex m, 7H), 1.45-1.60 (brm, 4H), 1.63-1.81 (brm, 8H),
10 1.82-1.95 (brm, 4H), 2.72-2.90 (brm, 1H), 3.10-3.30 (brm, 2H), 3.37-3.55 (m, 2H), 4.90-5.03 (m, 2H), 5.37-5.52 (brs, 1H), 6.71-6.90 (complex m, 4H), 7.20-7.32 (m, 2H), 7.44 (s, 1H), 8.55-8.80 (brs, 1H), 9.90-10.20 (brs, 1H); MS (ES) *m/z* (relative intensity): 585 (M⁺ - HCl), 532 (10).

EXAMPLE 11**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclopentyl) ester**

15 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclopentanol as a yellow gum according to the procedure of Example 1, leaving out the final HCl(g)/Et₂O hydrochloride salt forming step: ¹H NMR (300 MHz, CDCl₃): δ 1.07 (d, J=6.2 Hz, 3H), 1.50-2.00 (complex m, 16H), 2.52-2.70 (complex m, 3H), 2.85-2.95 (m, 2 H),
20 4.55-4.65 (m, 1H), 5.29-5.38 (m, 2H), 6.65-6.72 (m, 1H), 6.76 (s, 1H), 6.84 (d, J=8.0 Hz, 1H), 7.18-7.30 (m, 3H), 7.37 (s, 1H); MS (ES) *m/z* (relative intensity):
25 558 (M⁺, 100), 518 (10), 490 (20).

EXAMPLE 12**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid dioctyl ester**

30 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-octanol as a gummy white solid according to the procedure of Example 1, leaving out the final HCl(g)/Et₂O hydrochloride salt forming step: ¹H NMR (300 MHz, CDCl₃): δ 0.78-
35 0.90 (m, 6H), 0.95-1.40 (brm, 23H), 1.52-1.87 (m, 6H), 2.55-2.75 (brs, 1H), 2.89-

- 29 -

3.30 (brm, 4H), 4.12-4.33 (m, 4H), 5.15-5.35 (brs, 1H), 6.60-6.81 (m, 3H), 7.12-7.45 (m, 4H); MS (EI) *m/z* (relative intensity): 645 (M^+ , 5), 504 (100), 348 (100), 319 (100), 180 (100).

5

EXAMPLE 13**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dipentyl ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-pentanol as a brown gum according to the procedure of Example 1, leaving out the final $HCl_{(g)}/Et_2O$ hydrochloride salt forming step: 1H NMR (300 MHz, $CDCl_3$): δ 0.90 (t, $J=6.9$ Hz, 3H), 1.21-1.41 (brm, 10H), 1.67 (t, $J=7.0$ Hz, 4H), 1.80-2.10 (brs, 1H), 2.80 (t, $J=6.5$ Hz, 1H), 3.05-3.19 (brm, 2H), 3.45 (d, $J=10.4$ Hz, 2H), 4.28 (t, $J=6.7$ Hz, 4H), 5.46 (d, $J=9.6$ Hz, 1H), 5.50-5.90 (brs, 1H), 6.71-6.90 (m, 3H), 7.20-7.35 (m, 3H), 7.43 (s, 1H), 8.76 (brs, 1H), 1.05 (brs, 1H); MS (ES) *m/z* (relative intensity): 562 (M^+ , 100).

20

EXAMPLE 14**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dihexyl ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-hexanol as a white solid according to the procedure of Example 1, leaving out the final $HCl_{(g)}/Et_2O$ hydrochloride salt forming step: 1H NMR (300 MHz, $CDCl_3$): δ 0.75-0.90 (m, 6H), 1.00-1.41 (brm, 15H), 1.47-1.85 (m, 6H), 2.60-3.50 (brm, 5H), 4.15-4.30 (m, 4H), 5.18-5.35 (brs, 1H), 6.67-6.82 (m, 3H), 7.15-7.45 (m, 4H); MS (ES) *m/z* (relative intensity):

30

- 30 -

EXAMPLE 15

Carbonic acid 3-chloro-benzyl ester 2-(3-chloro-benzyloxycarbonyloxy)-4-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-phenyl ester

5

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 3-chlorobenzyl alcohol as a tan solid according to the procedure of Example 1, leaving out the final $\text{HCl}_{(\text{g})}/\text{Et}_2\text{O}$ hydrochloride salt forming step: ^1H NMR (300 MHz, CDCl_3): δ 1.28 (d, $J=6.3$ Hz, 3H), 1.80-2.40 (brs, 1H), 2.79 (t, $J=8.8$ Hz, 1H), 3.05-3.17 (brm, 2H), 3.37-3.49 (m, 2H), 5.23 (s, 4H), 5.43 (m, 1H), 6.72-6.88 (m, 3H), 7.10-7.44 (complexm, 12H), 8.76 (brs, 1H), 10.02 (brs, 1H); MS (ES) m/z (relative intensity): 670 (M^+ , 100)

10

15

EXAMPLE 16

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-phenyl-ethyl) ester

20

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-phenylethanol as a gummy tan solid according to the procedure of Example 1, leaving out the final $\text{HCl}_{(\text{g})}/\text{Et}_2\text{O}$ hydrochloride salt forming step: ^1H NMR (300 MHz, CDCl_3): δ 0.90-1.22 (m, 6H), 1.30-1.61 (m, 6H), 2.39-2.70 (brm, 1H), 2.83-3.19 (brm, 2H), 3.20-3.50 (brm, 2H), 5.15-5.35 (brs, 1H), 5.90-6.02 (brm, 1H), 6.45-6.82 (m, 3H), 7.11-7.40 (m, 4H), 8.64 (brs, 1H), 9.45 (brs, 1H); MS (ES) m/z (relative intensity): 630 (M^+ , 100).

25

EXAMPLE 17

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diheptyl ester

30

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-heptanol as a brown gum according to the procedure of Example 1, leaving out the final $\text{HCl}_{(\text{g})}/\text{Et}_2\text{O}$ hydrochloride salt forming step: ^1H NMR (300 MHz, CDCl_3): δ 0.80-0.92 (m, 6H),

35

1.23-1.40 (brm, 19H), 1.60-1.75 (m, 4H), 2.80 (t, J=8.8 Hz, 1H), 3.05-3.30 (brm, 2H), 3.38-3.50 (m, 2H), 4.27 (q, J=6.7 Hz, 4H), 5.43 (d, J=8.4 Hz, 1H), 6.72-6.90 (m, 4H), 7.20-7.33 (m, 2H), 7.44 (s, 1H), 8.70 (brs, 1H), 10.10 (brs, 1H); MS (ES) *m/z* (relative intensity): 618 (M^+ , 100).

5

EXAMPLE 18**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dinonyl ester**

10 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-nonanol as a brown gum according to the procedure of Example 1, leaving out the final $HCl_{(g)}/Et_2O$ hydrochloride salt forming step: 1H NMR (300 MHz, $CDCl_3$): δ 0.88 (t, J=6.8 Hz, 9H), 1.25-1.40 (m, 22H), 1.54-1.60 (m, 2H), 1.63-1.74 (m, 4H), 2.79 (brt, J = 8.8
15 Hz, 1H), 3.08-3.30 (m, 2H), 3.40-3.55 (m, 2H), 4.28 (t, J=6.8 Hz, 4H), 5.46 (d, J=8.7 Hz, 1H), 6.70-6.90 (m, 3H), 7.15-7.35 (m, 3H), 7.43 (s, 1H), 8.72 (brs, 1H), 9.98 (brs, 1H); MS (ES) *m/z* (relative intensity): 674 (M^+ , 100), 548 (M^+ - C_9H_{20} , 5).

EXAMPLE 19

20 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-decyl ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-decanol as a
25 brown gum according to the procedure of Example 1, leaving out the final $HCl_{(g)}/Et_2O$ hydrochloride salt forming step: 1H NMR (300 MHz, $CDCl_3$): δ 0.88 (t, J=6.8 Hz, 9H), 1.15-1.40 (m, 24H), 1.52-1.60 (m, 4H), 1.62-1.74 (m, 4H), 2.80 (brt, J = 8.8 Hz, 1H), 3.08-3.28 (m, 2H), 3.35-3.52 (m, 2H), 4.28 (t, J=6.7 Hz, 4H), 5.45 (d, J=8.8 Hz, 1H), 6.70-6.90 (m, 3H), 7.18-7.35 (m, 3H), 7.43 (s, 1H), 8.71 (brs, 1H),
30 10.02 (brs, 1H); MS (ES) *m/z* (relative intensity): 702 (M^+ , 100).

- 32 -

EXAMPLE 20**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid didodecyl ester**

5 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-dodecanol as a brown gum according to the procedure of Example 1, leaving out the final $\text{HCl}_{(g)}/\text{Et}_2\text{O}$ hydrochloride salt forming step: ^1H NMR (300 MHz, CDCl_3): δ 0.88 (t, $J=6.8$ Hz, 9H), 1.20-1.40 (m, 30H), 1.51-1.60 (m, 4H), 1.62-1.73 (m, 4H), 2.75-2.85 (m, 1H), 3.05-3.25 (m, 2H), 3.35-3.52 (m, 2H), 4.28 (t, $J=6.8$ Hz, 4H), 5.45 (d, $J=8.8$ Hz, 1H), 6.60-6.90 (m, 3H), 7.17-7.40 (m, 3H), 7.43 (s, 1H), 8.78 (brs, 1H), 10.05 (brs, 1H); MS (ES) m/z (relative intensity): 594 (M^+ , 100).

EXAMPLE 21

15 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isopropoxy-ethyl) ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-isopropoxyethanol as a brown solid according to the procedure of Example 1, leaving out the final $\text{HCl}_{(g)}/\text{Et}_2\text{O}$ hydrochloride salt forming step: ^1H NMR (300 MHz, CDCl_3): δ 1.11 (d, $J=6.1$ Hz, 12H), 1.30 (d, $J=6.2$ Hz, 3H), 2.79 (t, $J=8.7$ Hz, 1H), 3.06-3.28 (m, 2H), 3.40-3.60 (m, 2H), 3.62-3.70 (complexm, 4H), 3.90-4.12 (brm, 2H), 4.35-4.45 (complexm, 4H), 5.43 (d, $J=8.7$ Hz, 1H), 6.61-6.90 (m, 3H), 7.11-7.32 (m, 3H), 7.44 (m, 1H), 8.70 (brs, 1H), 9.92 (brs, 1H); MS (ES) m/z (relative intensity): 758 (M^+ , 30), 546 (100).

EXAMPLE 22

30 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid isopropyl ester**

To a stirred solution of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropyl ester hydrochloride salt (3.0 g, 5.53 mmol) and 20 mL of *i*-PrOH was added 1N NaOH (11.1 mL, 11.1 mmol). After stirring at 23 °C for 3 days, the mixture was concentrated to

- 33 -

dryness, dissolved in 10 % MeOH/CH₂Cl₂, and filtered through a small pad of silica gel. The filtrate was concentrated to a colorless gum, and triturated with Et₂O to give 1.0 g (39 %) of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid isopropyl ester as a white solid; ¹H NMR (300 MHz, CDCl₃): δ 0.93 (d, J=6.1 Hz, 3H), 1.17 (d, J=6.3 Hz, 6H), 2.30-2.53 (m, 2H), 2.67-2.80 (m, 2H), 2.85-3.00 (m, 1H), 4.65-4.75 (brs, 1H), 4.91 (hept, J=6.3 Hz, 1H), 6.52-6.80 (complexm, 3H), 7.17-7.45 (complexm, 4H); MS (ES) *m/z* (relative intensity): 464 (M⁺, 100).

10

EXAMPLE 23

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid ethyl ester

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester hydrochloride according to the procedure of Example 22 as a brown solid: ¹H NMR (300 MHz, CDCl₃): δ 1.20 (d, J=6.7 Hz, 3H), 1.33 (t, J=7.1 Hz, 3H), 2.70 (m, 1H), 2.90-3.22 (m, 4H), 3.23-3.48 (m, 1H), 4.34 (q, J=7.1 Hz, 2H), 5.30 (m, 1H), 6.55-6.90 (m, 3H), 7.10-7.45 (m, 4H); MS (ES) *m/z* (relative intensity): 450 (M⁺+1, 50).

20

EXAMPLE 24

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-methoxycarbonylmethyl ester

25

Step 1

5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester

30

To a stirred solution of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diethyl ester hydrochloride salt (5.0 g, 9.72 mmol), and THF (90 mL) was added *i*-Pr₂NEt (4.23 mL, 3.14 g, 24.3 mmol) and (Boc)₂O (2.12 g, 9.72 mmol). After 6 h, an additional portion of (Boc)₂O (200 mg, 0.92 mmol) is added. After a total of 22 h, the solution was quenched with 10 mL of sat. aq. NaHCO₃, and extracted with 3 x 100 mL Et₂O. The combined organics

35

- 34 -

were washed with 1 x 150 mL of brine, dried over MgSO_4 , filtered and concentrated to a yellow oil. Flash chromatography on silica gel, eluting with hexanes/EtOAc (2/1) gave 5.07 g (90 %) of product as a sticky, off-white solid; ^1H NMR (300 MHz, CDCl_3): δ 1.22 (d, $J = 6.9$ Hz, 3H), 1.30-1.47 (m, 15H), 2.47-2.54 (m, 1H), 2.57-2.70 (m, 1H), 3.05-3.15 (m, 1H), 3.46-3.68 (m, 1H), 4.08-4.18 (m, 1H), 4.29-4.42 (m, 4H), 4.75 (brd, $J = 8.6$ Hz, 1H), 5.51 (brs, 1H), 6.55-6.88 (complexm, 4H), 7.20-7.44 (m, 3H); MS (ES) m/z (relative intensity): 578 (M^+ , 1), 504 (20), 336 (60), 298 (20), 198 (100), 180 (40).

10

Step 2

5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid

To a stirred solution of 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester (4.42 g, 7.65 mmol), MeOH (100 mL) and H_2O (25 mL) was added 5 N NaOH (7.64 mL, 38.2 mmol). After 19 h, the solution was concentrated to an aqueous mixture and acidified to pH = 1 with 1 N aq. HCl which turns the solution milky-white. Extraction with 3 x 100 mL EtOAc, washing the combined organics with 1 x 200 mL brine, drying over Na_2SO_4 , filtration and concentration gave 3.96 g (99 %) of product as a white solid; ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 1.16 (d, $J = 6.7$ Hz, 3H), 1.31 (s, 9H), 2.55-2.70 (m, 1H), 2.80-2.92 (m, 1H), 3.05-3.23 (m, 2H), 3.71-3.93 (m, 2H), 4.62-4.87 (m, 2H), 5.30-5.90 (brs, 1H), 6.59-6.99 (complexm, 4H), 7.14-7.47 (complexm, 3H), 8.60-8.80 (brs, 1H); MS (ES) m/z (relative intensity): 522. ($\text{M}^+ + \text{H}$, 50).

25

Step 3

5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-methoxycarbonyl-methyl ester

30

To a stirred solution of 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (500 mg, 0.96 mmol) and DMF (10 mL) was added K_2CO_3 (132 mg, 0.96 mmol) and methyl-2-bromoacetate (0.23 mL, 366 mg, 2.40 mmol). After stirring at 50 °C for 4 h, the

35

- 35 -

reaction mixture was cooled to 23 °C, quenched with 5 mL sat. aq. NaHCO₃, and extracted with 3 x 30 mL of EtOAc. The combined organics were washed with 2 x 50 mL brine, dried over MgSO₄, filtered and concentrated to a yellow oil. Flash chromatography on silica gel, eluting with hexane/EtOAc (4/1 to 2/1), gave 508 mg (79 %)
5 of product as a colorless oil; ¹H NMR (300 MHz, CDCl₃): δ 1.22 (d, J = 6.9 Hz, 3 H), 1.41 (brs, 9H), 2.50-2.60 (brm, 1H), 2.60-2.75 (brm, 1H), 3.06-3.15 (brm, 1H), 3.45-3.60 (brm, 1H), 3.76 (s, 3H), 3.77 (s, 3H), 4.05-4.20 (brm, 1H), 4.70-4.79 (brm, 1H), 4.79(s, 2H), 4.80(s, 2H), 5.42-5.51 (brs, 1H), 6.60-6.91 (complexm, 4H), 7.20-7.43(complexm, 3H); MS (ES) *m/z* (relative intensity): 666
10 (M⁺, (100), 610 (25).

Step 4

**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]-
15 dioxole-2,2-dicarboxylic acid bis-methoxycarbonylmethyl ester**

To a stirred solution of 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-methoxycarbonyl-methyl ester (330 mg, 0.50 mmol) and CH₂Cl₂ (10 mL) was added trifluoroacetic acid (0.08 mL, 113 mg, 0.99 mmol). After stirring at 23 °C for 1 h,
20 additional trifluoroacetic acid (0.08 mL, 113 mg, 0.99 mmol) was added. After a total of 22 h, the mixture was quenched with 5 mL of sat. aq. NaHCO₃, and extracted with 3 x 30 mL of EtOAc. The combined organics were washed with 1 x 50 mL of brine, dried over MgSO₄, filtered and concentrated to a yellow oil. Flash chromatography on silica gel, eluting with CHCl₃/MeOH (20/1 to 10/1) gave 145 mg (52 %) of product as
25 a white gum; ¹H NMR (300 MHz, CDCl₃): δ 1.33 (m, 3H), 1.70-2.40 (brm, 2H), 2.73-2.90 (brt, 1H), 3.04-3.30 (m, 2H), 3.37-3.53 (m, 2H), 3.75 (s, 3H), 3.76 (s, 3H), 4.80 (s, 2H), 4.81 (s, 2H), 5.40 (m, 1H), 6.73-6.93 (complexm, 4H), 7.15-7.32 (m, 2H), 7.43 (s, 1H); MS (ES) *m/z* (relative intensity): 566 (M⁺, 80), 508 (M⁺ - CO₂CH₃+H, 100), 450 (M⁺ - 2CO₂CH₃+2H, 30).

30

- 36 -

EXAMPLE 25

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propoxycarbonylmethyl ester

5

Step 1

5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propoxycarbonylmethyl ester

10

The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and propyl 2-bromoacetate according to the procedure of Example 24, step 3 as a colorless oil: ¹H NMR (300 MHz, CDCl₃): δ 0.91 (t, J=7.4 Hz, 6H), 1.21 (d, J=6.9 Hz, 3H), 1.40 (s, 9H), 1.55-1.72 (m, 4H), 2.47-2.70 (m, 1H), 3.05-3.17 (m, 1H), 3.46-3.60 (m, 1H), 4.11 (t, J=6.6 Hz, 4H), 4.70-4.85 (m, 4H), 5.47 (s, 1H), 6.60-6.92 (m, 3H), 7.20-7.35 (m, 3H), 7.41 (s, 1H); MS (ES) *m/z* (relative intensity): 722 (M⁺, 100).

15

20

Step 2

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propoxycarbonylmethyl ester

25

The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propoxyoxycarbonylmethyl ester according to the procedure of Example 24, step 4 as a brown gum: ¹H NMR (300 MHz, CDCl₃): δ 0.80-0.95 (m, 9H), 1.40-1.80 brm, 6H), 2.80-3.74 (brm, 7H), 4.05-4.20 (m, 4H), 4.70-4.85 (m, 2H), 5.10 (brs, 1H), 6.70-6.95 (brm, 3H), 7.15-7.40 (brm, 4H); MS (ES) *m/z* (relative intensity): 622 (M⁺, 100).

30

EXAMPLE 26

**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methoxycarbonyl-ethyl)
ester**

5 **Step 1**

**5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-
amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-
methoxycarbonyl-ethyl)ester**

10 The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-
phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and
methyl 1-bromopropionate according to the procedure of Example 24, step 3 as a
colorless oil : ¹H NMR (300 MHz, CDCl₃): δ 1.22 (d, J=6.9 Hz, 3H), 1.38 (s, 9H),
2.50-2.70 (m, 2H), 2.89 (s, 3H), 2.96 (s, 3H), 3.07-3.15 (m, 1H), 3.45-3.60 (m,
15 1H), 3.70-3.83 (m, 8H), 4.05-4.18 (m, 1H), 4.72-4.80 (m, 1H), 5.22-5.32 (m, 1H),
6.60-6.90 (m, 3H), 7.20-7.32 (m, 3H), 7.41 (s, 1H); MS (ES) *m/z* (relative intensity):
694 (M⁺, 100), 638 (M⁺-*t*-Bu, 20), 594 (M⁺-Boc, 20).

Step 2

20 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methoxycarbonyl-
ethyl)ester**

25 The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-
phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid
bis-methoxycarbonyl-1-ethyl ester according to the procedure of Example 24, step 4 as
a colorless gum: ¹H NMR (300 MHz, CDCl₃): δ 1.28 (d, J=6.7 Hz, 3H), 1.30-2.00
(brm, 2H), 1.55-1.65 (m, 6H), 2.70-2.80 (m, 1H), 3.05-3.30 (m, 2H), 3.35-3.69
(m, 2H), 3.68-3.80 (m, 6H), 5.10-5.18 (m, 1H), 5.22-5.31 (m, 2H), 6.70-6.95 (m,
30 3H), 7.15-7.30 (m, 3H), 7.36 (s, 1H); MS (ES) *m/z* (relative intensity): 594 (M⁺,
100).

- 38 -

EXAMPLE 27

5-(2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropoxycarbonylmethyl ester

5

Step 1

5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropoxycarbonyl-methyl ester

10

The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and isopropyl 2-bromoacetate according to the procedure of Example 24, step 3 as a colorless oil: ¹H NMR (300 MHz, CDCl₃): δ 1.15-1.30 (m, 15H), 1.40 (s, 9H), 2.45-2.70 (m, 2H), 3.06-3.15 (m, 1H), 3.45-3.60 (m, 1H), 4.05-4.18 (m, 2H), 4.70-4.80 (m, 4H), 5.06 (sept, J=6.3 Hz, 2H), 5.46 (brs, 1H), 6.60-6.90 (m, 3H), 7.20-7.35 (m, 3H), 7.41 (s, 1H).; MS (ES) *m/z* (relative intensity): 722 (M⁺, 100).

15

Step 2

5-(2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropoxycarbonylmethyl ester

20

The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropoxycarbonylmethyl ester according to the procedure of Example 24, step 3 as a brown gum: ¹H NMR (300 MHz, CDCl₃): δ 1.17-1.30 (m, 15H), 2.72-2.82 9m, 1H), 3.10-3.29 (m, 3H), 3.38-3.50 (m, 1H), 4.70-4.80 (m, 4H), 4.95-5.18 (complexm, 3H), 6.72-6.95 (m, 3H), 7.15-7.30 (m, 3H), 7.36 (s, 1H), 8.73 (brs, 1H), 9.86 (brs, 1H); MS (ES) *m/z* (relative intensity): 622 (M⁺, 100).

25

EXAMPLE 28

**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-
dicarboxylic acid bis-ethoxycarbonylmethyl ester**

5

Step 1

**5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-
amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-
ethoxycarbonyl methylester**

10

The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and ethyl bromoacetate according to the procedure of Example 24, Step 3 as a colorless oil; ¹H NMR (300 MHz, CDCl₃): δ 1.17-1.30 (m, 9H), 1.39 (s, 9H), 2.48-2.54 (brm, 1H), 2.55-2.61 (brm, 1H), 3.07-3.13 (m, 2H), 3.47-3.55 (brm, 1H), 4.05-4.20 (brm, 1H), 4.21 (q, J = 7.0 Hz, 4H), 4.20-4.33 (brm, 1H), 4.78 (s, 2H), 4.79 (s, 2 H), 5.45-5.50 (brm, 1 H), 6.61-6.85 (m, 4H), 7.20-7.43 (m, 3H); MS (ES) *m/z* (relative intensity): 694 (M⁺, (100), 638 (15), 594 (15).

20

Step 2

**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]
dioxole-2,2-dicarboxylic acid bis-ethoxycarbonylmethyl ester**

25

The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethoxycarbonylmethyl ester according to the procedure of Example 24, Step 4 as a white gum; ¹H NMR (300 MHz, CDCl₃): δ 1.15-1.27 (m, 3H), 1.31-1.41 (t, J=6.8 Hz, 6H), 2.53-3.51 (m, 6H), 3.60-3.80 (m, 4H), 4.00-4.10 (brs, 1H), 4.15-4.30 (q, J=6.7 Hz, 4H), 4.70-4.85 (brm, 1H), 6.60-6.95 (m, 3H), 7.10-7.50 (m, 4H); MS (ES) *m/z* (relative intensity): 594 (M⁺, 10), 522 (80), 508 (80), 436 (100).

30

- 40 -

EXAMPLE 29

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-ethoxycarbonyl-ethyl) ester

5

Step 1

5-(2-{tert-Butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-ethoxycarbonyl-ethyl) ester

10

The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and ethyl 2-bromopropionate according to the procedure of Example 24, Step 3 as a colorless oil; ¹H NMR (300 MHz, CDCl₃): δ 1.15-1.30 (complex m, 9H), 1.40 (brs, 9H), 1.52-1.69 (m, 6H), 2.47-2.58 (m, 1H), 2.58-2.70 (m, 1H), 3.05-3.16 (m, 1H), 3.42-3.54 (m, 1H), 4.05-4.30 (complexm, 5H), 4.77 (m, 1H), 5.19-5.30 (m, 2H), 5.49 (brs, 1H), 6.57-6.67 (m, 1H), 6.71-6.80 (m, 1H), 6.82-6.91 (m, 2H), 7.20-7.35 (m, 2H), 7.41 (brs, 1H); MS (ES) *m/z* (relative intensity): 722 (M⁺, 100).

15

20

Step 2

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-ethoxycarbonyl-ethyl) ester The title compound was prepared from 5-(2-{tert-butoxycarbonyl-[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethoxycarbonyl-1-ethyl ester according to the procedure of Example 24, Step 4 as a colorless oil; ¹H NMR (300 MHz, CDCl₃): δ very complex due to 4 diastereomers present; MS (ES) *m/z* (relative intensity): 622 (M⁺, 40), 522 (M⁺-CH₃CHCO₂Et, 100).

25

EXAMPLE 30**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-trimethylsilanylmethyl ester**

5 Acetyl chloride (0.59 g, 7.5 mmol) was added to trimethylsilylmethanol (4.03 g, 37.5 mmol) with stirring at room temperature. After 0.5 h, 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (1.05 g, 2.5 mmol) was added in portions. The resulting solution was stirred for 3 days, and then treated with 50 ml of 50% sodium bicarbonate solution, followed by
10 extraction with ethyl acetate (50 ml). The organic extract was dried over anhydrous sodium sulfate, filtered, and evaporated. The residue was passed through a pad of silica gel, eluting with hexanes, and ether-hexanes/1:1 until no more trimethylsilylmethanol could be detected. The filter pad was then eluted with ethyl acetate, and the solvent was evaporated to give 1.14 g of the desired product as a colorless gum. Conversion to the
15 HCl salt yielded 1.16 g of white foam; ^1H NMR (CDCl_3) δ 0.06 (s, 18 H), 1.33 (d, J = 6.5 Hz, 3 H), 2.80 (m, 1H), 3.15 (m, 1H), 3.20 (m, 1 H), 3.48 (m, 2 H), 4.014 (s, 2 H), 4.015 (s, 2 H), 5.45 (bd, J = 9.7 Hz, 1 H), 5.60 (bs, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.45 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1763 cm^{-1} (C=O); MS (ES) m/z 594 (MH^+); $[\alpha]_{\text{D}}^{25} -23^\circ$ (c, 1.0, CHCl_3). Anal. Calcd. for
20 $\text{C}_{28}\text{H}_{40}\text{ClNO}_7\text{Si}_2\cdot\text{HCl}$: C, 53.32; H, 6.39; N, 2.22; Cl, 11.24; Si, 8.91. Found: C, 52.65; H, 6.70; N, 2.11; Cl, 11.47; Si, 9.00.

EXAMPLE 31**25 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-trimethylsilanyl-ethyl) ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-
30 trimethylsilylethanol according to the procedure of Example 30 as a white foam (HCl salt); ^1H NMR (CDCl_3) δ 0.03 (s, 18 H), 1.06 (t, J = 8.6 Hz, 4 H), 1.33 (bs, 3 H), 1.90 (bs, 1H), 2.80 (bs, 1H), 3.18 (bs, 2H), 3.48 (bs, 2 H), 4.37 (t, J = 8.6 Hz, 4 H), 5.45 (bs, 1 H), 6.80 (m, 3 H), 7.26 (m, 2 H), 7.43 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1763 cm^{-1} (C=O); MS (ES) m/z 622 (MH^+); $[\alpha]_{\text{D}}^{25} -23^\circ$ (c,

1.0, CHCl₃). Anal. Calcd. for C₃₀H₄₄ClNO₇Si₂·HCl: C, 54.70; H, 6.88; N, 2.13; Cl, 10.76; Si, 8.53. Found: C, 53.96; H, 7.05; N, 1.86; Cl, 8.84; Si, 10.33.

EXAMPLE 32

5 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-trimethylsilanyl-propyl) ester**

10 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 3-trimethylsilylpropanol according to the procedure of Example 30 as a white foam (HCl salt); ¹H NMR (CDCl₃) δ 0.01 (s, 18 H), 0.46 (m, 4 H), 1.33 (d, J = 6.3 Hz, 3 H), 1.70 (m, 4 H), 2.80 (m, 1H), 3.18 (m, 2H), 3.46(m 2 H), 4.24(t, J = 7.0 Hz, 4 H), 5.47 (bd, J = 9.7 Hz, 1 H), 5.70 (bs, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.43 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (ES) m/z 650 (MH⁺); [α]_D²⁵ -22° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₂H₄₈ClNO₇Si₂·HCl: C, 55.96; H, 7.04; N, 2.04 Cl, 10.32; Si, 8.18. Found: C, 55.82; H, 7.21; N, 1.87; Cl, 10.22; Si, 7.76.

20

EXAMPLE 33

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3,3-dimethyl-butyl) ester

25 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 3,3-dimethylbutanol according to the procedure of Example 30 as a white foam (HCl salt); ¹H NMR (CDCl₃) δ 0.90 (s, 18 H), 1.33 (bs, 3 H), 1.62 (t, J = 7.4 Hz, 4 H), 2.80 (bs, 1H), 3.18 (bs, 2H), 3.48 (bs, 2 H), 4.35 (t, J = 7.4 Hz, 4 H), 5.45 (bs, 1 H), 6.80 (m, 3 H), 7.26 (m, 2 H), 7.43 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (CI) m/z 590 (MH⁺); [α]_D²⁵ -24° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₂H₄₄ClNO₇·HCl: C, 61.34; H, 7.08; N, 2.24; Cl, 11.32. Found: C, 60.79; H, 7.46; N, 2.09; Cl, 11.95.

30

EXAMPLE 34

5-(2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclohexylmethyl ester

5 The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclohexylmethanol according to the procedure of Example 30 as a white foam (HCl salt); ¹H NMR (CDCl₃) δ 0.80-1.80 (m, 22 H), 1.33 (bs, 3 H), 2.80 (m, 1H), 3.18 (m, 2H), 3.48 (m, 2 H), 4.10 (m, 4 H), 5.50 (bs, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.43 (s, 1 H),
10 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (CI) m/z 614 (MH⁺); [α]_D²⁵ -22° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₄H₄₄ClNO₇·HCl: C, 62.77; H, 6.82; N, 2.15; Cl, 10.90. Found: C, 61.83; H, 7.27; N, 2.07; Cl, 10.25.

EXAMPLE 35

15 5-(2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-methyl-pentyl) ester

The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 4-methylpentanol according to the procedure of Example 30 as a colorless gum (HCl salt); ¹H NMR (CDCl₃) δ 0.87 (d, J = 6.5 Hz, 12 H), 1.33 (bs, 3 H), 1.10-2.0 (m, 10 H), 2.80 (bs, 1H), 3.18 (bs, 2H), 3.48 (bs, 2 H), 4.28(m, 4 H), 5.60 (bs, 2 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.43 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (CI) m/z 590 (MH⁺); [α]_D²⁵ -24° (c, 1.0, CHCl₃). Anal. Calcd. for
25 C₃₂H₄₄ClNO₇·HCl: C, 61.34; H, 7.08; N, 2.24; Cl, 11.32. Found: C, 60.50; H, 7.36; N, 2.13; Cl, 11.66.

EXAMPLE 36

30 5-(2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclohexyl-ethyl) ester

The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-cyclohexylethanol according to the procedure of Example 30 as an off-white foam (HCl salt); ¹H NMR

- 44 -

(CDCl₃) δ 0.80-1.80 (m, 26 H), 1.32 (d, J = 6.3 Hz, 3 H), 2.80 (m, 1H), 3.18 (m, 2H), 3.48 (m, 2 H), 4.32 (t, J = 6.9 Hz, 4 H), 5.45 (bd, J = 9.7 Hz, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.45 (s, 1 H), 8.70 (bs, 1 H), 10.0 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (CI) m/z 642 (MH⁺); $[\alpha]_D^{25}$ -24° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₆H₄₈ClNO₇·HCl: C, 63.71; H, 7.13; N, 2.06; Cl, 10.45. Found: C, 63.07; H, 7.54; N, 2.07; Cl, 12.81.

EXAMPLE 37

5-**{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propyl) ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 3-cyclopentylpropanol according to the procedure of Example 30 as a colorless gum (HCl salt); ¹H NMR (CDCl₃) δ 0.80-1.80 (m, 26 H), 1.33 (d, J = 6.3 Hz, 3 H), 2.80 (m, 1H), 3.18 (m, 2H), 3.48 (m, 2 H), 4.28 (t, J = 6.8 Hz, 4 H), 5.45 (bd, J = 9.7 Hz, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.45 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (CI) m/z 642 (MH⁺); $[\alpha]_D^{25}$ -21° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₆H₄₈ClNO₇·HCl: C, 63.71; H, 7.13; N, 2.06; Cl, 10.45. Found: C, 63.69; H, 7.64; N, 2.00; Cl, 10.13.

EXAMPLE 38

5-**{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclopropylmethyl ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclopropylmethanol according to the procedure of Example 30 as a white solid (HCl salt); ¹H NMR (CDCl₃) δ 0.33 (m, 4 H), 0.61 (m, 4 H), 1.21, (m, 2 H), 1.32 (bs, 3 H), 2.80 (m, 1H), 3.19 (m, 2H), 3.48 (m, 2 H), 4.15 (d, J = 7.3 Hz, 4 H), 5.50 (bd, 1 H), 5.70 (bs, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.45 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1757, 1778 cm⁻¹ (C=O); MS (ES) m/z 530 (MH⁺); $[\alpha]_D^{25}$ -26° (c, 1.0,

- 45 -

CHCl₃). Anal. Calcd. for C₂₈H₃₂ClNO₇·HCl: C, 59.37; H, 5.69; N, 2.47; Cl, 12.53. Found: C, 59.19; H, 5.88; N, 2.29; Cl, 12.87.

EXAMPLE 39

5 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-
cyclopropylmethyl) ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-methylcyclopropyl-methanol according to the procedure of Example 30 as a white solid (HCl salt); ¹H NMR (CDCl₃) δ 0.39 (m, 4 H), 0.52 (m, 4 H), 1.10, (s, 6 H), 1.32 (d, J = 6.5 Hz, 3 H), 2.80 (m, 1H), 3.19 (m, 2H), 3.48 (m, 2 H), 4.10 (s, 4 H), 5.50 (bd, 1 H), 5.70 (bs, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.45 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1763 cm⁻¹ (C=O); MS (ES) m/z 558 (MH⁺); [α]_D²⁵ -25° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₀H₃₆ClNO₇·HCl: C, 60.61; H, 6.10; N, 2.36; Cl, 11.94. Found: C, 60.02; H, 6.58; N, 2.17; Cl, 11.20.

EXAMPLE 40

20 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclobutylmethyl ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclobutylmethanol according to the procedure of Example 30 as an off-white solid (HCl salt); ¹H NMR (CDCl₃) δ 1.32 (d, J = 6.5 Hz, 3 H), 1.85 (m, 8 H), 2.05 (m, 4 H), 2.69 (m, 2 H), 2.80 (m, 1H), 3.19 (m, 2H), 3.48 (m, 2 H), 4.10 (s, 4 H), 5.50 (bd, 1 H), 5.70 (bs, 1 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.45 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1759, 1779 cm⁻¹ (C=O); MS (ES) m/z 558 (MH⁺); [α]_D²⁵ -27° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₀H₃₆ClNO₇·HCl: C, 60.61; H, 6.10; N, 2.36; Cl, 11.94. Found: C, 60.68; H, 6.30; N, 2.31; Cl, 11.71.

- 46 -

EXAMPLE 41**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclopentyl-ethyl) ester**

5 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-cyclopentylethanol according to the procedure of Example 30 as an amber gum (HCl salt); ¹H NMR (CDCl₃) δ 1.32 (d, J = 6.3 Hz, 3 H), 1.60 (m, 20 H), 2.80 (m, 1H), 2.90 (m, 2 H), 3.15 (m, 1H), 3.20 (m, 1H), 3.48 (m, 2 H), 4.30 (t, J = 6.9 Hz, 4 H), 5.50 (bd, 1
10 H), 6.80 (m, 3 H), 7.25 (m, 2 H), 7.43 (s, 1 H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (CI) m/z 614 (MH⁺); [α]_D²⁵ -24° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₄H₄₄ClNO₇·HCl: C, 62.77; H, 6.82; N, 2.15; Cl, 10.90. Found: C, 64.04; H, 8.24; N, 1.62; Cl, 8.99.

15 **General Method to Prepare 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-acetoxy-alkyl esters**

Step 1**20 Preparation of Acyloxyalkyl Iodides**

These esters were prepared by reacting the appropriate acid chlorides with formaldehyde or acetaldehyde in the presence of a catalytic amount of anhydrous ZnCl₂ according to Ulich, L. H. and Adams, R. *J. Amer. Chem. Soc.* 1921, 43, 660- 666.

25 The resultant acyloxyalkyl chlorides were converted in to the corresponding acyloxyalkyl iodide derivatives by reacting them with NaI in boiling benzene according to Fujimoto, K., Ishihara, S., Yanagisawa, H., Ide, J., Nakayama, E., Nakao, H., Sugawara, S., Iwata, M. *J. Antibiotics* 1987, 19, 370.

- 47 -

Step 2**5-{2-[2-(3-Chlorophenyl)-2-hydroxyethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt**

5 To a stirred solution of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-
propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disodium salt (3.0 gm, 6.0 mmol) in
distilled water, (in the dark) a solution of AgNO₃ (2.3 g, 12.0 mmol) was added
dropwise. After stirring at room temperature for 1 h the separated solid was filtered
and washed with water and acetone. The solid was dried at room temperature under
10 vacuum to give a colorless solid; yield 100%; mp 183-185; M+H 422.1.

Step 3**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-acetoxyalkyl esters**

15 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-
propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in
anhydrous chloroform the appropriately substituted acyloxyalkyl iodide (9 mmol)
dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room
20 temperature, under dark for 16 h. The reaction mixture was filtered and washed with
5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over
anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained
was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated
solid was filtered and washed with hexane. The compounds of Examples 42-58 below
25 were prepared according to this general procedure.

EXAMPLE 42**5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]
dioxole-2,2-dicarboxylic acid bis-acetoxymethyl ester**

30 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-
propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in
anhydrous chloroform, acetoxymethyl iodide (9 mmol) dissolved in chloroform (30
mL) was added. The reaction mixture was stirred at room temperature, under dark for
35 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in

- 48 -

distilled water. The chloroform layer was dried over anhydrous MgSO_4 and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield an ivory color solid; mp 132-134; yield 97%; M+H 566.

5

EXAMPLE 43

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propionyloxymethyl ester

10 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform, propionyloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% $\text{Na}_2\text{S}_2\text{O}_3$ solution in
15 distilled water. The chloroform layer was dried over anhydrous MgSO_4 and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a colorless solid; mp 118-20; yield 88%; M+H 594.

20

EXAMPLE 44

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-butyryloxymethyl ester

25 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform butyryloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% $\text{Na}_2\text{S}_2\text{O}_3$ solution in distilled water. The chloroform layer was dried over anhydrous MgSO_4 and filtered.
30 It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 70-72 (dec); yield 85%; M+H 622.

EXAMPLE 45**5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isobutyryloxymethyl ester**

5 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform isobutyryloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in
10 distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 114-116 (dec); yield 78%; M+H 622.

15

EXAMPLE 46**5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-heptanoyloxymethyl ester**

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-
20 propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform heptanoyloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered.
25 It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 94-96; yield 18%; M+H 707.

EXAMPLE 47

30 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-methyl-pentanoyloxymethyl) ester**

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-
propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in
35 anhydrous chloroform pentanoyloxymethyl iodide (9 mmol) dissolved in chloroform

- 50 -

(30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 105-108 (dec); yield 19%; M+H 679.

EXAMPLE 48

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]
dioxole-2,2-dicarboxylic acid bis-hexanoyloxymethyl ester

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform hexanoyloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 106-109; yield 20%; M+H 679.

EXAMPLE 49

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]
dioxole-2,2-dicarboxylic acid bis- (2,2-dimethyl-propionyloxymethyl)
ester

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 2,2-dimethylpropionyloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a ivory solid; mp 72 (dec); yield, 48%; M+H 651.

EXAMPLE 50

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclohexanecarbonyloxymethyl ester

5

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform cyclohexanecarbonyloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 86 (dec); yield 52%; M+H 703.

15

EXAMPLE 51

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-propionyloxy-ethyl) ester

20

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 1-propionyloxyethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 130-132 (dec); yield, 68%; M+H 622

25

- 52 -

EXAMPLE 52

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(2,2-dimethyl-propionyloxy-ethyl) ester

5

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 1-(2,2-dimethylpropionyloxy)ethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 92; yield, 58%; M+H 679.

15

EXAMPLE 53

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3,3-dimethyl-butyryloxymethyl) ester

20

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 3,3-dimethylbutyryloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 104-105 (dDec); yield 98%; M+H 678.

30

- 53 -

EXAMPLE 54

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(3,3-dimethyl-butyryloxy)-ethyl]}ester

5
To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 3,3-dimethylbutyryloxyethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature,
10 under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 96-98 (dec); yield, 72%; M+H 706.

15

EXAMPLE 55

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propionyloxymethyl) ester

20

To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 3-cyclopentylpropionyloxy iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature,
25 under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 155-157 (dec); yield, 98%; M+H
30 730.

- 54 -

EXAMPLE 56

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-benzoyloxymethyl ester

5 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform benzoyloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for
10 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a white solid; mp 150-153 (dec); yield 98%; M+H 690.

EXAMPLE 57

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzoyloxy-ethyl) ester

20 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 1-benzoyloxyethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for
25 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield an ivory solid; mp 82-83 (dec); yield 96%; M+H 718.

30

EXAMPLE 58

5-{2-[2-(3-Chloro-phenyl)-2-hydroxyethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-butyryloxymethyl) ester

5 To a stirred suspension of 5-{2-[2-(3-chlorophenyl)-2-hydroxyethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid disilver salt (2.0 gms, 3 mmol) in anhydrous chloroform 2,2-dimethylbutyryloxymethyl iodide (9 mmol) dissolved in chloroform (30 mL) was added. The reaction mixture was stirred at room temperature, under dark for 16 h. The reaction mixture was filtered and washed with 5% Na₂S₂O₃ solution in distilled water. The chloroform layer was dried over anhydrous MgSO₄ and filtered. It was evaporated to dryness and the residue obtained was dissolved in 5 mL of ethyl acetate and 60 mL of hexane was added. The separated solid was filtered and washed with hexane to yield a ivory solid; mp 121-123 (dec); yield 37%; M+H 679.

15

EXAMPLE 59

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(cyclohexyloxycarbonyloxy)-ethyl] ester

20

Cyclohexyl 1-iodoethyl carbonate (5.6 g, 18.8 mmol) in CHCl₃ (10 mL) was added dropwise into a cold (0 °C) suspension of (R, R)-5-[2-[2-(3-chlorophenyl)-2-hydroxyethylamino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid disilver salt (4.0 g, 6.3 mmol) and CHCl₃ (100 mL). After the addition, the mixture was allowed to come to room temperature and stirred for 24 h. Diethyl ether (300 mL) was added into the reaction mixture and the precipitated solids were filtered and discarded. The filtrate was concentrated in vacuo at room temperature and the residue was quickly chromatographed through silica gel, eluting anhydrous solvent (EtOAc / hexane, 1/1), to give a light yellow solid (1.25 g, 26% yield): mp 78-81 °C; (+)FAB m/e 762 (M+H)⁺. Analysis for: C₃₈H₄₈ClNO₁₃: Calcd: C, 59.89; H, 6.35; N, 1.84; Found: C, 60.88; H, 6.53; N, 1.99

30

- 56 -

EXAMPLE 60**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-amide**

5 A mixture of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester (2.4 g, 5 mmol) and ammonia (excess) was stirred for 48 h. The reaction mixture was concentrated and the residue obtained was extracted with chloroform : methanol (3:1). It was washed with water and dried over anhydrous MgSO₄. The organic layer was filtered and concentrated.

10 The residue obtained was chromatographed over silica gel eluted with 9:1 chloroform : methanol to yield a brown solid; mp 98; yield. 1.0 g; 45%; M+H 420.

EXAMPLE 61

15 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-2-propyl amide**

A mixture of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester (2.4 g, 5 mmol) and isopropylamine (10 mL, excess) was refluxed in ethanol for 48 h. The reaction mixture was

20 concentrated and the residue obtained was extracted with chloroform : methanol (3:1). It was washed with water and dried over anhydrous MgSO₄. The organic layer was filtered and concentrated. The residue obtained was chromatographed over silica gel eluted with 9:1 chloroform : methanol to yield a colorless spongy solid; mp 60; yield 1.5 g; 60%; M+H 504.

25

EXAMPLE 62

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-n-butyl amide

30 A mixture of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester (2.4 g, 5 mmol) and n-butylamine (10 mL, excess) was refluxed in ethanol for 48 h. The reaction mixture was concentrated and the residue obtained was extracted with chloroform : methanol (3:1). It was washed with water and dried over anhydrous MgSO₄. The organic layer was

35 filtered and concentrated. The residue obtained was chromatographed over silica gel

- 57 -

eluted with 9:1 chloroform : methanol to yield a brown semi solid; yield 1.6 g; 61%; M+H 532.

EXAMPLE 63

5 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-phenylmethyl amide**

A mixture of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester (2.4 g, 5 mmol) and
10 benzylamine (10 mL, excess) was refluxed in ethanol for 48 h. The reaction mixture
was concentrated and the residue obtained was extracted with chloroform : methanol
(3:1). It was washed with water and dried over anhydrous MgSO₄. The organic layer
was filtered and concentrated. The residue obtained was chromatographed over silica
gel eluted with 9:1 chloroform : methanol to yield a colorless spongy solid; mp 101;
15 yield 2.0 g; 67%; M+H 600.

EXAMPLE 64

20 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-furanylmethyl) amide**

A mixture of 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester (2.4 g, 5 mmol) and 2-
furanylmethylamine (10 mL, excess) was refluxed in ethanol for 48 h. The reaction
mixture was concentrated and the residue obtained was extracted with chloroform :
25 methanol (3:1). It was washed with water and dried over anhydrous MgSO₄. The
organic layer was filtered and concentrated. The residue obtained was
chromatographed over silica gel eluted with 9:1 chloroform : methanol to yield a brown
solid; mp 50; yield 400 mg; 14%; M+H 581.

30 EXAMPLE 65

**5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-
benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(glycine ethyl ester) amide**

A mixture of glycine ethyl ester.HCl (1.1 gm, 8 mmol) and sodium methoxide
35 (424 mg, 8 mmol) was stirred at room temperature in ethanol for fifteen minutes. At

- 58 -

the end, 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethyl ester (970 mg, 2 mmol) was added to the reaction mixture and refluxed for 48 hours. At the end ethanol was removed. The residue obtained was added to ice cold water and separated solid was filtered. The solid was dried and purified by silica gel column chromatography by eluting it with 3:1 chloroform:methanol to yield a colorless solid; yield 500 mg; 42%; M+H 592.

EXAMPLE 66

10 5-{2-[2-(3-Chloro-phenyl)-3-oxazolidinyl]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid sodium salt (0.46 g, 1.0 mmol) was dissolved in 4 mL of 37% formaldehyde, and stirred at room temperature for 0.5 h. Trifluoroacetic acid (0.23 g, 2.0 mmol) was then added dropwise, and the resulting white suspension was stirred for 24 h. The precipitate was filtered, washed with water, and dried in vacuo to give 0.40 g of white solid; ^1H NMR (CDCl_3) δ 1.02 (d, J = 6.4 Hz, 3 H), 2.50 (m, 1 H), 3.00 (m, 2H), 3.20 (m, 1 H), 3.80 (m, 1 H), 4.75 (d, J = 4.5 Hz, 1 H), 4.90 (d, J = 4.5 Hz, 1 H), 5.12 (t J = 7.3 Hz, 1 H), 6.70 (m, 1 H), 6.86 (m, 2 H), 7.40 (m, 2 H), 7.50 (s, 1 H); IR (KBr): 1740 cm^{-1} (C=O); MS (CI) m/z 433 (M^+). Anal. Calcd. for $\text{C}_{21}\text{H}_{20}\text{ClNO}_7\cdot\text{HCl}$: C, 58.14; H, 4.65; N, 3.23; Cl, 8.17. Found: C, 57.08; H, 4.78; N, 3.32; Cl, 7.51.

EXAMPLE 67

25 5-((2R)-2-{tert-Butoxycarbonyl-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-diethylcarbamoylemethyl ester

A mixture of 5-((2R)-2-{tert-butoxycarbonyl-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (0.26 g, 0.5 mmol) and anhydrous potassium carbonate (0.28 g) in anhydrous dimethyl formamide was treated with 2-bromo-N,N-diethylacetamide (0.39 g, 2 mmol), and stirred at room temperature for 3 days. It was then diluted with water and hexanes, and the resulting suspension was filtered. The precipitate was washed with saturated sodium bicarbonate solution, water, and hexanes, and then dried in vacuo to give 0.27 g of white solid; ^1H

- 59 -

NMR (CDCl₃) δ 1.0-1.5 (m, 24 H), 2.6 (m, 2H), 3.0-3.5 (m, 10H), 4.0 (m, 1 H), 4.7-5.0 (m, 4H), 5.5, 6.0 (m, 1 H), 6.80 (m, 3 H), 7.26 (m, 2 H); IR (KBr): 1772, 1668 cm⁻¹ (C=O); MS (ES) m/z 748 (MH⁺).

5

EXAMPLE 68

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-diethylcarbamoylmethyl ester

10 A solution of 5-((2R)-2-{tert-butoxycarbonyl-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-diethylcarbamoylmethyl ester (0.16 g, 0.2 mmol) in methylene chloride (2 ml) was treated with 0.08 ml of trifluoroacetic acid at room temperature for 18 h. The mixture was then evaporated, and the residue washed with ether to give 0.12 g of white solid (TFA salt);
15 ¹H NMR (DMSO-d₆) δ 1.0-1.2 (m, 15 H), 2.6 (m, 2H), 3.0-4.0 (m, 11H), 5.0 (m, 4 H), 6.1 (m, 1 H), 6.80 (m, 3 H), 7.26 (m, 2 H), 8.7 (bs, 1 H), 9.2 (bs, 1 H); IR (KBr): 1765, 1654 cm⁻¹ (C=O); MS (ES) m/z 648 (MH⁺).

EXAMPLE 69

20 **5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid cyclopropylmethyl ester**

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclopropylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO) δ
25 0.25 (q, 2H), 0.49 (q, 2H), 1.01 (d, 3H), 1.10 (m, 1H), 2.49 (m, 1H), 2.85-3.20 (m, 4H), 3.94 (d, 2H), 4.85 (bt, 1H), 6.58 (d, 1H), 6.76 (m, 2H), 7.35 (m, 3H), 7.46 (s, 1H); IR (KBr): 1653 cm⁻¹ (C=O), 1747 cm⁻¹ (C=O); MS (CI) m/z 476 (MH⁺).
Anal. Calcd. for C₂₄H₂₆ClNO₇: C, 60.57; H, 5.51; N, 2.94; Cl, 7.46. Found: C,
30 56.38; H, 5.16; N, 2.61; Cl, 7.60.

EXAMPLE 70

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid cyclobutylmethyl ester

5 The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclobutylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO) 8.01 (d, 3H), 1.75(m, 4H), 1.92(m, 2H), 2.49 (m, 1H), 2.65 (m, 1H), 2.85-3.20 (m, 4H), 4.09 (d, 2H), 4.85 (bt, 1H), 6.58 (d, 1H), 6.76 (m, 2H), 7.35(m, 3H),
10 7.46(s, 1H); IR (KBr): 1652 cm⁻¹(C=O), 1761 cm⁻¹ (C=O); MS (CI) m/z 490 (MH⁺). Anal. Calcd. for C₂₅H₂₈ClNO₇: C, 61.29; H, 5.76; N, 2.86; Cl, 7.24. Found: C, 57.13; H, 5.15; N, 2.43; Cl, 6.83.

EXAMPLE 71

15 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis 2-(3-Thienyl)ethyl- ester

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-(3-thienyl)ethanol
20 according to the procedure of Example 1 as yellow crystals (HCl salt); ¹H NMR (CDCl₃) 8.1.33 (d, 3 H), 2.82 (m, 1H), 2.95 (t, 4H), 3.20(m, 2H), 3.48 (bd, 2 H), 4.45 (t, 4 H), 5.50 (bd, 1 H), 5.60(bs, 1H), 6.75-7.00(m, 7H), 7.21-7.32(m, 5H), 7.45(s, 1H), 8.70 (bs, 1 H), 10.10 (bs, 1 H); IR (KBr): 1765 cm⁻¹ (C=O); MS (CI) m/z 642 (MH⁺); [α]_D²⁵ -21° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₄H₃₂ClS₂NO₇·HCl:
25 C, 56.63; H, 4.75; N, 2.06; S, 9.45; Cl, 10.46. Found: C, 55.89; H, 4.95; N, 1.87; S, 9.45; Cl, 9.95.

EXAMPLE 72

30 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid 2-(3-Thienyl)ethyl ester

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis 2-(3-thienyl)ethyl-ester according to the procedure of Example 22 as an off-white solid; ¹H NMR

- 61 -

(DMSO) δ 0.96 (d, 3H), 2.45 (m, 1H), 2.72-3.10 (m, 6H), 4.25 (t, 2H), 4.80 (bt, 1H), 5.92 (bs, 1H), 6.60 (d, 1H), 6.79 (d, 2H), 7.05 (d, 1H), 7.17 (s, 1H), 7.30-7.50 (5H); IR (KBr): 1652 cm^{-1} (C=O), 1751 cm^{-1} (C=O); MS (CI) m/z 532 (MH⁺). Anal. Calcd. for $\text{C}_{26}\text{H}_{26}\text{ClSNO}_7$: C, 58.70; H, 4.93; N, 2.63; S, 6.01; Cl, 5.98. Found: C, 54.17; H, 4.44; N, 2.24; S, 5.13; Cl, 5.98.

EXAMPLE 73

5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis 2-(Chloro)ethyl ester

10

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-chloroethanol according to the procedure of Example 1 as yellow crystals (HCl salt); ¹H NMR (DMSO) δ 1.13 (d, 3 H), 2.65 (m, 1H), 3.15-3.52 (m, 4H), 3.85 (t, 4 H), 4.60 (t, 4 H), 5.55 (bd, 1 H), 6.40 (bs, 1H), 6.86 (d, 1H), 7.08 (m, 2H), 7.40-7.58 (m, 4H), 8.85 (bs, 1 H), 9.40 (bs, 1 H); IR (KBr): 1770 cm^{-1} (C=O); MS (CI) m/z 548 (MH⁺); $[\alpha]_D^{25}$ -28° (c, 1.0, DMSO). Anal. Calcd. for $\text{C}_{24}\text{H}_{26}\text{Cl}_3\text{NO}_7\cdot\text{HCl}$: C, 49.42; H, 4.67; N, 2.40; Cl, 25.9. Found: C, 49.69; H, 4.38; N, 2.32; Cl, 23.20.

20

EXAMPLE 74

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-ethylbutyl) ester

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-ethylbutanol according to the procedure of Example 1 as an off-white gum (HCl salt); ¹H NMR (CDCl_3) δ 0.80-0.95 (m, 12 H), 1.25-1.45 (m, 10 H), 1.50-1.65 (m, 3 H), 2.75-2.85 (m, 1H), 3.10-3.40 (m, 1H), 3.47-3.49 (m, 2 H), 4.25 (d, 5 H), 5.50 (d, 1 H), 6.70-6.80 (m, 1 H), 6.80-6.90 (m, 2 H), 7.20-7.45 (m, 3 H), 7.46 (s, 1 H), 8.74 (bs, 1 H), 10.06 (bs, 1 H); IR (KBr): 2964 cm^{-1} (-OH), 1766 cm^{-1} (C=O); MS (ES) m/z 590.4 (MH⁺); $[\alpha]_D^{25}$ -21° (c, 1.0, CHCl_3). Anal. Calcd. for $\text{C}_{32}\text{H}_{44}\text{ClNO}_7\cdot\text{HCl}$: C, 61.34; H, 7.08; N, 2.24; Cl, 11.32. Found: C, 61.09; H, 7.46; N, 2.12; Cl, 10.77.

EXAMPLE 75**5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-methylbutyl)ester**

5 The title compound was prepared from 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and 3-methylbutanol according to the procedure of Example 1 as an off-white foam (HCl salt); ¹H NMR (CDCl₃) δ 0.90 (d, 12 H), 1.35 (d, 2 H), 1.55-1.80 (m, 6H), 2.70-2.85 (m, 1H), 3.45-3.55 (m, 3 H), 4.30 (t, 4 H), 5.45 (bd, 1 H), 5.65 (bs, 1 H), 6.70-6.80 (m, 1 H), 6.80-6.90 (m, 3 H), 7.25-7.35 (m, 3H), 7.43 (s, 1H), 8.74 (bs, 1 H), 10.08 (bs, 1 H); IR (KBr): 3303 cm⁻¹ (-OH), 1765 cm⁻¹ (C=O); MS (ES) m/z 562.4 (MH⁺); [α]_D²⁵ -24° (c, 1.0, CHCl₃). Anal. Calcd. for C₃₀H₄₀ClNO₇·HCl: C, 60.20; H, 6.74; N, 2.34; Cl, 11.85. Found: C, 59.98; H, 7.04; N, 2.24; Cl, 12.09.

15

EXAMPLE 76**5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (3-methylbutyl)ester**

20 The title compound was prepared from 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-methylbutyl)ester according to the procedure of Example 22 as an off-white solid; ¹H NMR (DMSO) δ 0.80-0.85 (m, 6H), 1.02-1.09 (m, 3H), 1.45 (q, 2H), 1.55-1.70 (m, 1H), 3.01-3.05 (m, 2H), 3.15-3.25 (m, 1H), 3.26-3.40 (m, 2H), 4.15 (t, 2H), 5.00-5.08 (m, 1H), 6.45 (bs, 1H), 6.55-6.65 (m, 1H), 6.75-6.90 (m, 2H), 7.45-7.49 (m, 5H), 7.51 (s, 1H); IR (KBr): 3394 cm⁻¹ (-OH), 1651 cm⁻¹ (C=O); MS (ES) m/z 492.0 (MH⁺); [α]_D²⁵ -22° (c, 1.0, CHCl₃). Anal. Calcd. for C₂₅H₃₀ClNO₇: C, 61.04; H, 6.15; N, 2.85; Cl, 7.20. Found: C, 59.80; H, 6.10; N, 2.89; Cl, 7.10.

25

EXAMPLE 77**30 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-adamantan-1-ylmethyl ester**

The title compound was prepared from 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and adamantan-1-

- 63 -

ylmethanol according to the procedure of Example 1 as a white solid (HCl salt); ^1H NMR (CDCl_3) δ 1.25 (m, 2H), 1.35 (d, 3 H), 1.51 (s, 12 H), 1.55-1.61 (m, 2H), 1.61-1.67 (m, 4 H), 1.67-1.75 (m, 6 H), 1.97 (s, 4 H), 3.20 (s, 2H), 3.42-3.49 (m, 2H), 3.88 (s, 4H), 4.11-4.16 (q, 1H), 5.45 (bd, 1H), 5.65 (bd, 1H), 6.75 (m, 1H), 6.78-6.89 (m, 2H), 7.23-7.30 (m, 3H), 7.44 (s, 1H), 8.74 (bs, 1H), 10.115 (bs, 1H); IR (KBr) 3418 cm^{-1} (-OH), 1767 cm^{-1} (C=O); MS (ES) m/z 718.4 (MH^+); $[\alpha]_{\text{D}}^{25}$ -15° (c, 1.0, CHCl_3). Anal. Calcd. for $\text{C}_{42}\text{H}_{52}\text{ClNO}_7$: C, 68.94; H, 9.22; N, 1.90; Cl, 9.40. Found: C, 67.48; H, 7.49; N, 1.48; Cl, 8.10.

10

EXAMPLE 78

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-propyl) ester

15 The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2,2-dimethylpropanol according to the procedure of Example 1 as an off-white foam (HCl salt); ^1H NMR (CDCl_3) δ .924 (s, 18 H), 1.45 (d, 2H), 1.75 (s, 2H), 2.80 (m, 1H), 3.17 (m, 1H), 3.45 (m, 1H), 3.98 (s, 4H), 5.45-5.55 (bd, 1H), 5.63-5.67 (bs, 1H), 20 6.75-6.80 (m, 2H), 6.80-6.89 (m, 2H), 7.25-7.35 (m, 3H), 7.440 (s, 1H), 8.75 (bs, 1H), 10.10 (bs, 1H); IR (KBr) 3355 cm^{-1} (-OH), 1767 cm^{-1} (C=O); MS (ES) m/z 562.3 (MH^+); $[\alpha]_{\text{D}}^{25}$ -23° (c, 1.0, CHCl_3). Anal. Calcd. for $\text{C}_{30}\text{H}_{40}\text{ClNO}_7$: C, 60.20; H, 6.90; N, 2.34; Cl, 11.85. Found: C, 59.74; H, 6.97; N, 2.23; Cl, 11.60.

25

EXAMPLE 79

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid adamantan-1-ylmethyl ester

30 The title compound was prepared from 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-adamantan-1-ylmethyl ester according to the procedure of Example 22 as an off-white solid; ^1H NMR (DMSO) δ 1.03-1.09 (m, 3H), 1.44 (s, 6 H), 1.45-1.64 (m, 8H), 1.86 (s, 4H), 3.02-3.15 (m, 1H), 3.25-3.55 (m, 2H), 3.70-3.80 (m, 2H), 4.58 (s, 2H), 5.06-5.10 (m, 1H), 6.52-6.65 (m, 1H), 6.79-6.88 (m, 2H), 7.32-7.49 (m, 3H), 7.49 (s, 1H);

IR (KBr) 3384 cm^{-1} (-OH), 1758 cm^{-1} (C=O), 1651 cm^{-1} (C=O); MS (ES) m/z 570.3 (MH^+); $[\alpha]_{\text{D}}^{25}$ -29° (c, 1.0, CHCl_3). Anal. Calcd. for $\text{C}_{31}\text{H}_{36}\text{ClNO}_7$: C, 65.31; H, 6.37; N, 2.46; Cl, 6.39. Found: C, 64.19; H, 6.20; N, 2.33; Cl, 6.33.

5

EXAMPLE 80

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (2,2-dimethyl-propyl)ester

The title compound was prepared from 5-((2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-propyl) ester according to the procedure of Example 22 as a white solid; ^1H NMR (DMSO) δ 0.868 (s, 9 H), 1.02-1.06 (m, 3H), 3.00-3.02 (m, 1H), 3.24-3.30 (m, 1H), 3.35 (s, 5H), 3.80 (t, 2H), 4.55 (s, 1H), 5.03 (m, 1H), 6.52 (m, 1H), 6.61 (m, 1H), 6.79 (m, 1H), 7.34 (m, 3H), 7.48 (s, 1H); IR (KBr) 3398 cm^{-1} (-OH), 1748 cm^{-1} (C=O), 1654 cm^{-1} (C=O); MS (ES) m/z 492.3 (MH^+); $[\alpha]_{\text{D}}^{25}$ -93° (c, 1.0, CHCl_3). Anal. Calcd. for $\text{C}_{25}\text{H}_{30}\text{ClNO}_7$: C, 61.04; H, 6.15; N, 2.85; Cl, 7.21. Found: C, 56.96; H, 5.65; N, 2.63; Cl, 7.05.

EXAMPLE 81

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (3,3-dimethylbutyl) ester

The title compound was prepared from 5-((2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-methyl-butyl)ester according to the procedure of Example 22 as an off-white solid; ^1H NMR (DMSO) δ 0.87 (s, 9 H), 1.04 (m, 3H), 1.50 (t, 2 H), 3.34 (s, 8H), 4.20 (t, 2H), 4.95-5.05 (m, 1H), 6.35 (m, 1H), 6.60 (m, 1H), 6.75 (m, 1H), 7.34-7.46 (m, 3H), 7.48 (s, 1H); IR (KBr) 3410 cm^{-1} (-OH), 1745 cm^{-1} (C=O), 1651 cm^{-1} (C=O); MS (ES) m/z 506.4 (MH^+); Anal. Calcd. for $\text{C}_{26}\text{H}_{32}\text{ClNO}_7$: C, 61.72; H, 6.37; N, 2.77; Cl, 7.01. Found: C, 60.69; H, 6.20; N, 2.63; Cl, 7.06.

EXAMPLE 82

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclohexylmethyl) ester.

5

The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-methylcyclohexyl-methanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.84 (s, 6H, CH₃, CH₃), 1.09 (d, *J* = 6.4 Hz, 3H, CH₃), 1.1-1.4 (m, 20H, cyclohexyl), 2.6 (m, 1H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 4.04 (s, 4H, OCH₂, OCH₂), 5.05 (m, 1H, CH), 6.35 (d, *J* = 4.17 Hz, 1H, OH), 6.85 (dd, *J* = 7.9, 1.32 Hz, 1H, Ar-H), 7.07 (s, 1H, Ar-H), 7.09 (d, *J* = 8.35 Hz, Ar-H), 7.38-7.42 (m, 3H, Ar-H), 7.5 (s, 1H, Ar-H), 8.8 (brs, 1H, NH), 9.4 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 641 (M⁺); Analysis for: C₃₆H₄₈ClNO₇·xHCl: Calc'd: C, 63.71; H, 7.28; N, 2.06; Found: C, 63.72; H, 7.03; N, 1.91.

15

EXAMPLE 83

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclohexyl-2-methyl-propyl) ester.

20

The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-cyclohexyl-2-methylpropanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 1.1 (s, 6H, CH₃, CH₃), 1.45 (s, 6H, CH₃, CH₃), 1.5 (s, 6H, CH₃, CH₃), 2.6 (m, 1H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 4.04 (s, 4H, OCH₂, OCH₂), 5.05 (m, 1H, CH), 6.35 (d, *J* = 4.17 Hz, 1H, OH), 6.85 (dd, *J* = 7.9, 1.32 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.38-7.42 (m, 3H, Ar-H), 7.5 (s, 1H, Ar-H), 8.8 (brs, 1H, NH), 9.4 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 698 (M+H)⁺; Analysis for: C₄₀H₅₆ClNO₇·xHCl: Calc'd: C, 65.38; H, 7.82; N, 1.91; Found: C, 65.32; H, 7.96; N, 1.94.

25

30

- 66 -

EXAMPLE 84

5-**[(2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methyl-2-nitro-propyl) ester.**

5

The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-methyl-2-nitropropanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.78 (s, 12H, 4 x CH₃), 0.8-1.0 (m, 4H, CH₂), 1-1.2 (m, 11H, cyclohexyl, CH₃), 1.5-1.65 (m, 10H, cyclohexyl), 2.6 (m, 1H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 4.04 (s, 4H, OCH₂, OCH₂), 5.05 (m, 1H, CH), 6.35 (d, *J* = 4.17 Hz, 1H, OH), 6.83 (dd, *J* = 7.9, 1.32 Hz, 1H, Ar-H), 7.06 (s 1H, Ar-H), 7.09 (d, *J* = 8.35 Hz), 7.38-7.42 (m, 3H, Ar-H), 7.5 (s, 1H, Ar-H), 8.8 (brs, 1H, NH), 9.4 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); Analysis for: C₂₈H₃₄ClN₃O₁₁·xHCl: Calc'd: C, 50.92; H, 5.34; N, 6.36; Found: C, 50.72; H, 5.42; N, 5.96.

10

15

EXAMPLE 85

5-**[(2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2,4-trimethyl-pentyl) ester.**

20

The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2,2,4-trimethylpentanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.65-0.9 (m, 24H, 8 x CH₃), 1.09 (d, *J* = 6.4 Hz, 3H, CH₃), 1.1-1.4 (m, 4H, CH₂, CH₂), 2.62 (m, 1H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 4.04 (s, 4H, OCH₂, OCH₂), 5.05 (m, 1H, CH), 6.34 (d, *J* = 3.95 Hz, 1H, OH), 6.85 (dd, *J* = 7.9, 1.32 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.38-7.42 (m, 3H, Ar-H), 7.5 (s, 1H, Ar-H), 8.7 (brs, 1H, NH), 9.1 (brs, 1H, NH); IR (KBr, cm⁻¹) 3300 (OH), 2900 (NH), 1760 (CO); MS *m/e* 646 (M+H)⁺; Analysis for: C₃₆H₅₂ClNO₇·xHCl: Calc'd: C, 63.33; H, 7.83; N, 2.05; Found: C, 62.96; H, 7.71; N, 2.44.

25

30

EXAMPLE 86

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-pentyl) ester.

5

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2,2-dimethylpentanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.8 (m, 18H, 6 x CH₃), 1.1-1.2 (m, 11H, CH₂ CH₃), 2.6 (m, 1H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 4.0 (s, 4H, OCH₂, OCH₂), 5.09 (m, 1H, CH), 6.36 (d, *J* = 4.17 Hz, 1H, OH), 6.86 (dd, *J* = 7.9, 1.32 Hz, 1H, Ar-H), 7.07 (s 1H, Ar-H), 7.09 (d, *J* = 8.35 Hz, Ar-H), 7.35-7.42 (m, 3H, Ar-H), 7.48 (s, 1H, Ar-H), 8.84 (brs, 1H, NH), 9.48 (brs, 1H, NH); IR (KBr, cm⁻¹) 3300 (OH), 2900 (NH), 1760 (CO); MS *m/e* 617 (M⁺); Analysis for: C₃₄H₄₈ClNO₇·xHCl: Calc'd: C, 62.38; H, 7.55; N, 2.14; Found: C, 62.47; H, 7.51; N, 2.31.

10

15

EXAMPLE 87

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-furan-3-ylmethyl) ester.

20

25

30

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and tetrahydrofuran-3-ylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 1.03 (d, *J* = 6.37 Hz, 3H, CH₃), 1.5 (m, 2H, CH₂), 1.9 (m, 2H, CH₂), 2.6 (m, 3H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 3.6-3.7 (m, 6H, CH₂), 4.1-4.15 (m, 6H, CH₂), 5.09 (m, 1H, CH), 6.36 (brs, 1H, OH), 6.86 (m, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.38-7.42 (m, 3H, Ar-H), 7.47 (s, 1H, Ar-H), 8.84 (brs, 2H, NH, NH); IR (KBr, cm⁻¹) 3300 (OH), 2900 (NH), 1760 (CO); MS *m/e* 590 (M+H)⁺; Analysis for: C₃₀H₃₆ClNO₉·xHCl: Calc'd: C, 57.51; H, 5.95; N, 2.24; Found: C, 57.80; H, 6.30; N, 2.21.

EXAMPLE 88

5-**[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-hydroxy-2,2,4-trimethyl-pentyl) ester.**

5

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclopropylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.7–0.95 (m, 27H, 9 x CH₃), 1.8 (m, 1H, CH), 2.1 (m, 1H, CH), 2.6 (m, 1H, CH), 3–3.4 (m, 6H, OH, CH, CH₂), 3.6–3.8 (brs, 2H, CH), 4.04 (m, 2H, OCH₂, OCH₂), 4.6 (m, 1H, CH), 4.85 (m, 1H, CH), 5.05 (m, 1H, CH), 6.35 (d, *J* = 3.7 Hz, 1H, OH), 6.85 (dd, *J* = 7.9, 1.32 Hz, 1H, Ar-H), 7.09 (m, 2H, Ar-H), 7.38–7.42 (m, 3H, Ar-H), 7.5 (s, 1H, Ar-H), 8.78 (brs, 1H, NH), 9.2 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1750 (CO); MS *m/e* 678 (M+H)⁺; Analysis for: C₃₆H₅₂ClNO₉·xHCl: Calc'd: C, 60.50; H, 7.47; N, 1.95; Found: C, 60.30; H, 8.09; N, 1.62.

10

15

EXAMPLE 89

5-**[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-3-phenyl-propyl) ester.**

20

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2,2-dimethyl-3-phenylpropanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.82 (s, 12H, 4 x CH₃), 1.08 (d, *J* = 6.37 Hz, 3H, CH₃), 2.6 (m, 1H, CH), 3–3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 3.96 (s, 4H, OCH₂, OCH₂), 5.04 (m, 1H, CH), 6.35 (d, *J* = 4.17 Hz, 1H, OH), 6.89 (dd, *J* = 8.13, 1.53 Hz, 1H, Ar-H), 7.05 (m, 4H, Ar-H), 7.14 (m, 8H, Ar-H), 7.38–7.42 (m, 3H, Ar-H), 7.5 (s, 1H, Ar-H), 8.81 (brs, 1H, NH), 9.38 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 714 (M+H)⁺; Analysis for: C₄₂H₄₈ClNO₇·xHCl: Calc'd: C, 67.19; H, 6.58; N, 1.87; Found: C, 66.69; H, 6.53; N, 1.83.

25

30

EXAMPLE 90

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-pyran-2-ylmethyl) ester.

5

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and tetrahydropyran-2-ylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 1.10 (d, *J* = 6.37 Hz, 3H, CH₃), 1.1-1.2 (m, 2H, CH₂), 1.3-1.6 (m, 8H, CH₂), 1.7-1.8 (m, 2H, CH₂), 2.6 (m, 1H, CH), 3-3.5 (m, 9H, CH, CH₂), 3.8 (m, 2H, CH), 4.19-4.2 (s, s, 4H, OCH₂, OCH₂), 5.04 (m, 1H, CH), 6.35 (d, *J* = 4.17 Hz, 1H, OH), 6.85 (d, *J* = 8.13 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.36-7.42 (m, 3H, Ar-H), 7.48 (s, 1H, Ar-H), 8.76 (brs, 1H, NH), 9.18 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 618 (M+H)⁺; Analysis for: C₃₂H₄₀ClNO₉xHCl: Calc'd: C, 58.72; H, 6.31; N, 2.14; Found: C, 57.97; H, 6.46; N, 2.08.

10

15

EXAMPLE 91

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-furan-2-ylmethyl) ester.

20

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and tetrahydrofuran-2-ylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 1.1 (d, *J* = 6.37 Hz, 3H, CH₃), 1.43-1.6 (m, 2H, CH₂), 1.65-1.8 (m, 4H, CH₂), 1.98-2.0 (m, 2H, CH₂), 2.6 (m, 1H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 3.57-3.7 (m, 4H, CH₂), 4.05 (m, 2H, CH₂), 4.2 (m, 2H, CH₂), 4.3 (m, 2H, CH₂), 5.04 (m, 1H, CH), 6.34 (d, *J* = 3.95 Hz, 1H, OH), 6.84 (dd, *J* = 8.13, 1.32 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.36-7.44 (m, 3H, Ar-H), 7.48 (s, 1H, Ar-H), 8.77 (brs, 1H, NH), 9.2 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 590 (M+H)⁺; Analysis for: C₃₀H₃₆ClNO₉xHCl: Calc'd: C, 57.51; H, 5.95; N, 2.24; Found: C, 56.37; H, 5.90; N, 2.20.

25

30

- 70 -

EXAMPLE 92

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(5-methyl-[1,3]dioxan-5-ylmethyl) ester.

5

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 5-methyl-[1,3]dioxan-5-ylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.7 (s, 3H, CH₃), 0.74 (s, 3H, CH₃), 1.1 (d, *J* = 6.59 Hz, 3H, CH₃), 2.6 (m, 1H, CH), 3-3.3 (m, 8H, CH, CH₂), 3.6-3.7 (m, 4H, CH₂), 4.6-4.8 (m, 4H, CH₂), 5.04 (m, 1H, CH), 6.34 (brs, 1H, OH), 6.84 (dd, *J* = 8.13, 1.32 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.36-7.44 (m, 3H, Ar-H), 7.48 (s, 1H, Ar-H), 8.77 (brs, 1H, NH), 9.2 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 650 (M+H)⁺; Analysis for: C₃₂H₄₀ClNO₁₁·xHCl: 15 Calc'd: C, 55.98; H, 6.02; N, 2.04; Found: C, 54.67; H, 6.58; N, 2.05.

EXAMPLE 93

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclohex-3-enylmethyl) ester.

20

The title compound was prepared from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 1-methylcyclohex-3-enylmethanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.84 (s, 6H, 2 x CH₃), 1.09 (d, *J* = 6.4 Hz, 3H, CH₃), 1.25-1.4 (m, 4H, CH₂), 1.6-1.65 (m, 2H, CH₂), 1.8-2.0 (m, 6H, CH₂), 2.6 (m, 1H, CH), 3-3.3 (m, 3H, CH, CH₂), 3.4 (brs, 1H, CH), 4.04 (m, 4H, OCH₂, OCH₂), 5.05 (m, 1H, CH), 5.55-5.65 (m, 4H, CH), 6.35 (d, *J* = 4.17 Hz, 1H, OH), 6.85 (dd, *J* = 7.9, 1.32 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.38-7.42 (m, 3H, Ar-H), 7.5 (s, 1H, Ar-H), 8.8 (brs, 1H, NH), 9.4 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 638 (M+H)⁺; Analysis for: C₃₆H₄₄ClNO₇·xHCl: 30 Calc'd: C, 64.09; H, 6.72; N, 2.08; Found: C, 64.69; H, 7.19; N, 1.67.

EXAMPLE 94

5-**[(2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-hydroxy-2,2-dimethyl-propyl) ester.**

5

The title compound was prepared from 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid 3-hydroxy-2,2-dimethyl-propanol according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO-*d*₆, 400MHz) δ 0.78 (s, 12H, 4 x CH₃), 1.09 (d, *J* = 6.4 Hz, 3H, CH₃), 2.6 (m, 1H, CH), 3-3.3 (m, 7H, CH, CH₂), 3.4 (brs, 1H, CH), 4.04 (s, 4H, OCH₂, OCH₂), 4.65 (m, 2H, OH), 5.05 (m, 1H, CH), 6.34 (d, *J* = 4.17 Hz, 1H, OH), 6.85 (dd, *J* = 7.9, 1.53 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.37-7.42 (m, 3H, Ar-H), 7.48 (s, 1H, Ar-H), 8.78 (brs, 1H, NH), 9.2 (brs, 1H, NH); IR (KBr, cm⁻¹) 3400 (OH), 2900 (NH), 1760 (CO); MS *m/e* 594 (M+H)⁺; Analysis for: C₃₀H₄₀ClNO₉·xHCl: 15 Calc'd: C, 57.14; H, 6.55; N, 2.22; Found: C, 56.44; H, 6.62; N, 2.38.

EXAMPLE 95

5-**[(2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-ethoxy-ethyl) ester**

20

Through a stirred room temperature solution of 8.0 g (0.019 mole) 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid and 30 mL of 2-ethoxyethanol was bubbled HCl(g) for 5 min. After heating at 100 °C for 12 h, TLC (9/1 CH₂Cl₂/MeOH) indicated the formation of both 5-[2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-ethoxy-ethyl) ester (*R*_f = 0.8; 9/1 CH₂Cl₂/MeOH) and 5-[(2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-ethoxy-ethyl) ester (*R*_f = 0.2; 9/1 CH₂Cl₂/MeOH). After cooling to room temperature, excess 2-ethoxyethanol was removed via Kugelrohr distillation (0.05 mm, oven temperature = 95 °C), and the brown residue was chromatographed on silica gel, eluting with 0 to 10% MeOH in CH₂Cl₂, to give 1.0 g (0.002 mole, a 10% yield) of the title compound as an off-white solid; ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.12 (m, *J* = 6.3 Hz, 3H), 2.5 (m, 3H), 3.35 (m, 8H), 5.06 (m, 1H), 6.3 (s, 1H, OH), 6.5 (m, 1H), 6.6 (m, 1H), 6.8 (m, 2H), 7.0 (m, 1H), 7.5 (m, 2H), 8.0 (m, 1H, NH), d 9.2 (m, 1H, COOH); MS (ES) *m/z* (relative intensity): 494 (M⁺+H, 100). 35

EXAMPLE 96

5-{{(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[2-(3-bromo-phenyl)-ethyl]ester hydrochloride salt

The title compound was prepared as a brown oil from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-(3-bromophenyl)ethanol according to the procedure of Example 1; ¹H NMR (300 MHz, CDCl₃): δ 1.12 (m, J = 6.3 Hz, 3H), 2.79 (m, 8H), 3.5 (m 2H), 4.18 (s, 1H, OH), 5.56 (m, 1H), 6.8 (m, 3H), 7.0 (m, 4H), 7.33 (m, 4H), 7.5 (m, 4H), 8.5 (m, 1H, NH); MS (ES) *m/z* (relative intensity): 788 (M⁺+H, 100).

EXAMPLE 97

15 5-{{(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-m-tolyl-ethyl) ester hydrochloride salt

The title compound was prepared as a brown oil from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 2-(3-methylphenyl)ethanol according to the procedure of Example 1; yield: 81%; ¹H NMR (300 MHz, CDCl₃): δ 1.12 (m, J = 6.3 Hz, 3H), 2.27 (s, 6H), 2.79 (m, 7H), 3.19 (m, 1H), 3.48 (m, 2H), 4.29 (m, J = 6.6 Hz, 4H), 5.49 (m, 1H), 6.75 (m, J = 8.1 Hz, 1H), 6.83 (m, 1H), 7.05 (m, 8H), 7.20 (m, 1H), 7.27 (m, 1H), 7.43 (s, 1H), 7.5 (m, 2H); MS (ES) *m/z* (relative intensity): 658 (M⁺+H, 100).

EXAMPLE 98

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester**Step 1****(R,R)-5-{2-[[2-(3-Chloro-phenyl)-2-hydroxy-ethyl]-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diethyl ester**

10 To a 0 °C solution of 3.0 g (5.83 mmol) (R,R)-5-{2-[[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid diethyl ester hydrochloride salt and 60 mL CH₂Cl₂ was added 2.54 mL (1.88 g, 14.57 mmol) of *i*-Pr₂NEt followed by 0.84 mL (1.30 g, 6.12 mmol) of 2,2,2-trichloroethyl chloroformate. After stirring at room temperature for 6 h, the reaction mixture was
15 quenched with 10 mL sat. aq. NaHCO₃, and extracted with 3 x 100 mL Et₂O. The combined organics were washed with 1 x 100 1N HCl, 1 x 100 mL brine, dried over MgSO₄, filtered and evaporated to a yellow oil. Flash chromatography on silica gel, eluting with hexanes/EtOAc (4/1 to 2/1), gives 3.46 g (5.30 mmol, a 91% yield) of the title compound (*R_f* = 0.32; 2/1 hexanes/EtOAc) as an oily, off-white solid; ¹H NMR
20 300 MHz, CDCl₃): δ 1.20-1.39 (complex m, 9H), 2.60-2.80 (m, 1H), 2.80-2.91 (m, 1H), 3.01-3.19 (m, 1H), 3.23-3.31 (m, 1H), 3.40-3.53 (m, 1H), 4.10-4.23 (m, 1H), 4.30-4.42 (complex m, 4H), 4.70-4.89 (m, 3H), 6.65-6.88 (complex m, 4H), 7.15-7.39 (complex m, 3H); MS (ES) *m/z* (relative intensity): 654 (M⁺ + H, 100).

Step 2**5-((2R)-2-(((2R)-2-(tert-Butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diethyl ester**

30 To a -78 °C solution of 3.75 g (5.47 mmol) (R,R)-5-{2-[[2-(3-chloro-phenyl)-2-hydroxy-ethyl]-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diethyl ester and 60 mL of CH₂Cl₂ was added 1.27 mL (1.17 g, 10.94 mmol) of 2,6-lutidine followed by 1.38 mL (1.59 g, 6.03 mmol) of TBSOTf. After stirring at -78 °C for 1.5 h, the reaction mixture was quenched with 50 mL sat.
35 aq. NaHCO₃ and warmed to room temperature. After extraction with 3 x 150 mL Et₂O,

- 74 -

the combined organics were washed with 1 x 200 mL sat. CuSO_4 , 1 x 200 mL brine, dried over MgSO_4 , filtered and evaporated to a cloudy white oil. Flash chromatography on silica gel, eluting with hexanes/EtOAc (8/1 to 4/1) gave 3.42 g (4.46 mmol, an 82% yield) of the title compound ($R_f = 0.31$; 4/1 hexanes/EtOAc) as a gummy colorless solid; ^1H NMR (300 MHz, CDCl_3): δ -0.13-(-0.08) (m, 3H), 0.00-0.06 (m, 3H), 0.85-0.91 (m, 9H), 1.05 (d, $J=6.7$ Hz, 3H), 1.33 (t, $J=7.1$ Hz, 6H), 2.60-2.75 (m, 1H), 2.77-2.96 (m, 1H), 3.00-3.31 (m, 2H), 3.77-4.00 (m, 1H), 4.35 (q, $J=7.1$ Hz, 4H), 4.65-4.88 (m, 2H), 5.02-5.20 (m, 1H), 6.60-6.85 (m, 4H), 7.15-7.37 (m, 3H); MS (ES) m/z (relative intensity): 790 ($\text{M}^+ + \text{Na}$, 100), 768 ($\text{M}^+ + \text{H}$, 20).

Step 3

5-((2R)-2-(((2R)-2-(tert-Butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid

To a room temperature solution of 3.31 g (4.31 mmol) 5-((2R)-2-(((2R)-2-(tert-butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diethyl ester, 100 mL MeOH and 25 mL H_2O was added 4.31 mL (21.56 mmol) of a 5N NaOH solution. After stirring at room temperature for 80 h, the solvent was evaporated, and the resulting slurry was acidified to pH 1 with 1 N HCl. The reaction mixture is extracted with 3 x 100 mL EtOAc, and the combined organics were washed with 2 x 30 mL brine, dried over Na_2SO_4 , filtered and evaporated to give 3.01 g (4.23 mmol, a 98% yield) of the title compound ($R_f = 0.0$; 10/1 $\text{CHCl}_3/\text{MeOH}$) as an off-white solid; ^1H NMR (300 MHz, CDCl_3): δ -0.19-(-0.11) (m, 3H), 0.01-0.09 (m, 3H), 0.81-0.91 (m, 9H), 0.93-0.97 (m, 3H), 2.55-2.97 (complex m, 3H), 3.07-3.35 (m, 2H), 3.80-4.40 (br m, 2H), 4.60-4.83 (m, 2H), 5.03-5.18 (m, 1H), 6.60-6.92 (m, 4H), 7.15-7.39 (m, 3H); MS (ES) m/z (relative intensity): 734 ($\text{M}^+ + \text{Na}$, 30), 712 ($\text{M}^+ + \text{H}$, 100).

- 75 -

Step 4

5-((2R)-2-(((2R)-2-(tert-Butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester

5

To a room temperature solution of 950 mg (1.34 mmol) 5-((2R)-2-(((2R)-2-(tert-butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and 15 mL DMF was added 267 mg (2.67 mmol) of KHCO_3 and 0.26 mL (471 mg, 2.80 mmol) of allyl iodide. After stirring at room temperature for 16 h, the reaction was quenched with 10 mL sat. aq. NaHCO_3 and extracted with 3 x 100 mL Et_2O . The combined organics were washed with 1 x 150 mL brine, dried over MgSO_4 , filtered and evaporated to a colorless oil. Flash chromatography on silica gel, eluting with hexanes/ EtOAc (8/1 to 4/1), gave 670 mg (0.85 mmol, a 63% yield) of the title compound ($R_f = 0.62$; 2/1 hexanes/ EtOAc) as a colorless oil; ^1H NMR (300 MHz, CDCl_3): δ -0.19-(-0.11) (m, 3H), 0.00-0.08 (m, 3H), 0.87 (s, 9H), 1.04 (d, $J=6.7$ Hz, 3H), 2.60-2.74 (m, 1H), 2.77-2.98 (m, 1H), 3.03-3.17 (m, 1H), 3.18-3.30 (m, 1H), 3.75-3.98 (m, 1H), 4.65-4.87 (m, 6H), 5.03-5.18 (m, 1H), 5.29 (d, $J=17.3$ Hz, 2H), 5.34 (d, $J=23.7$ Hz, 2H), 5.82-5.97 (complex m, 2H), 6.60-6.88 (m, 4H), 7.15-7.37 (m, 3H); MS (ES) m/z (relative intensity): 814 ($\text{M}^+ + \text{Na}$, 100).

10

15

20

Step 5

5-((2R)-2-(((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester

25

To a 0 °C solution of 650 mg (0.82 mmol) 5-((2R)-2-(((2R)-2-(tert-butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester and 20 mL THF was added 1.0 mL of HF-pyridine, and the reaction mixture was warmed to room temperature. After 22 h, TLC indicated that some starting material remained ($R_f = 0.62$ (2/1 hexanes/ EtOAc), and an additional 1.0 mL of HF-pyridine was added. After a total of 26 h, TLC indicated the disappearance of starting material and the formation of the title compound ($R_f = 0.28$ (2/1 hexanes/ EtOAc). The reaction mixture was slowly quenched with 30 mL of sat. aq. NaHCO_3 , extracted with 2 x 75 mL Et_2O and then

30

35

- 76 -

with 1 x 75 mL EtOAc. The combined organics were washed with 1 x 100 mL brine, dried over MgSO_4 , filtered and evaporated to a colorless oil. Flash chromatography on silica gel, eluting with hexanes/EtOAc (2/1), gave 460 mg (0.68 mmol, an 83% yield) of the title compound ($R_f = 0.28$; 2/1 hexanes/EtOAc) as a colorless oil; ^1H NMR (300 MHz, CDCl_3): δ 1.20-1.37 (m, 3H), 2.60-2.78 (m, 2H), 2.80-2.91 (m, 1H), 2.98-3.18 (m, 1H), 3.23-3.40 (m, 1H), 3.41-3.54 (m, 2H), 4.10-4.26 (br m, 1H), 4.73-4.92 (5H), 5.22-5.40 (complex m, 4H), 5.81-5.98 (complex m, 2H), 6.62-6.87 (m, 4H), 7.17-7.41 (m, 3H); MS (ES) m/z (relative intensity): 700 ($\text{M}^+ + \text{Na}$, 100).

10

Step 6

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester

A mixture of 370 mg (0.55 mmol) 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl)-((2,2,2-trichloro-ethoxycarbonyl)-amino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester, 10 mL glacial acetic acid and 357 mg (5.46 mmol) of Zn dust were stirred at room temperature for 40 h. The reaction mixture was filtered through celite, poured into 50 mL brine, and extracted with 3 x 50 mL EtOAc. The combined organics were washed with 3 x 75 mL sat. NaHCO_3 , 1 x 75 mL brine, dried over Na_2SO_4 , filtered and evaporated to a colorless oil. Flash chromatography on silica gel, eluting with $\text{CHCl}_3/\text{MeOH}$ (20/1 to 10/1), gave 180 mg (0.36 mmol, a 66% yield) of the title compound ($R_f = 0.35$; 10/1 $\text{CHCl}_3/\text{MeOH}$) as a colorless gum; ^1H NMR (300 MHz, CDCl_3): δ 1.20-1.33 (m, 3H), 2.70-2.81 (m, 1H), 3.00-3.19 (m, 2H), 3.36-3.45 (m, 2H), 4.50-5.50 (br s, 2H), 4.70-4.80 (m, 4H), 5.10-5.20 (m, 1H), 5.25-5.40 (m, 4H), 5.82-6.00 (complex m, 2H), 6.70-6.91 (m, 3H), 7.17-7.30 (m, 3H), 7.41 (s, 1H); MS (ES) m/z (relative intensity): 502 (M^+ , 100).

- 77 -

EXAMPLE 99

5-((2R)-2-(((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl)ester

5

Step 1

5-((2R)-2-(((2R)-2-(tert-Butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl) ester

10 The title compound was prepared as a colorless oil according to the procedure of Example 4, Step 4 except that cinnamyl bromide was used in place of allyl iodide; yield 66%; $R_f = 0.68$ (2/1 hexanes/EtOAc); $^1\text{H NMR}$ (300 MHz, CDCl_3): δ -0.19-(-0.11) (m, 3H), -0.01-0.05 (m, 3H), 0.83-0.90 (m, 9H), 1.02 (d, $J=6.7$ Hz, 3H), 2.60-2.75 (m, 1H), 2.77-2.96 (m, 1H), 3.04-3.33 (m, 2H), 3.76-4.00 (m, 1H), 4.65-
15 4.85 (m, 2H), 4.90-4.98 (m, 4H), 5.02-5.20 (m, 1H), 6.20-6.33 (m, 2H), 6.60-6.85 (m, 5H), 7.15-7.45 (m, 14H); MS (ES) m/z (relative intensity) 944 (M^+ , 100).

Step 2

20 **5-((2R)-2-(((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl) ester**

The title compound was prepared as a colorless oil according to the procedure of Example 4, Step 5 except that 5-((2R)-2-(((2R)-2-(tert-butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl) ester was used in place of
25 5-((2R)-2-(((2R)-2-(tert-butyl-dimethyl-siloxy)-2-(3-chloro-phenyl)-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester; yield 78%; $R_f = 0.31$ (2/1 hexanes/EtOAc); $^1\text{H NMR}$ (300 MHz, CDCl_3):
30 δ 1.20-1.35 (m, 3H), 2.58-2.80 (m, 1H), 2.81-3.20 (m, 2H), 3.22-3.56 (m, 2H), 4.10-4.31 (m, 3H), 4.70-4.95 (m, 5H), 6.17-6.43 (m, 2H), 6.60-6.90 (m, 5H), 7.15-7.45 (m, 14H).; MS (ES) m/z (relative intensity): 830 ($\text{M}^+ + \text{H}$, 100).

- 78 -

Step 3

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl)ester

The title compound was prepared as a colorless oil according to the procedure of Example 4, Step 6 except that 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl)-((2,2,2-trichloro-ethoxycarbonyl)-amino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl) ester was used in place of 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl)-((2,2,2-trichloro-ethoxycarbonyl)-amino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester; yield 59%; $R_f = 0.35$ (10/1 $\text{CHCl}_3/\text{MeOH}$); ^1H NMR (300 MHz, CDCl_3): δ 1.15 (d, $J=6.3$ Hz, 3H), 2.50-3.70 (brs, 2H), 2.60-2.71 (m, 1H), 2.80-2.92 (m, 2H), 2.95-3.15 (m, 2H), 4.83-4.95 (m, 5H), 5.25-5.40 (m, 4H), 6.08-6.30 (complex m, 2H), 6.66-6.91 (m, 5H), 7.15-7.40 (m, 14H); MS (ES) m/z (relative intensity): 654 (M^+ , 100).

15

EXAMPLE 100**5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid dicyclooctyl ester**

The title compound was prepared as a white gum from 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and cyclooctanol according to the procedure of Example 1; yield 84 %; $R_f = 0.30$ (10/1 $\text{CHCl}_3/\text{MeOH}$); ^1H NMR (300 MHz, CDCl_3): δ 1.30-1.39 (brd, 3H), 1.40-1.92 (m, 28H), 2.72-2.87 (m, 1H), 3.06-3.30 (m, 2H), 3.39-3.52 (m, 2H), 3.80-3.91 (m, 1H), 5.02-5.13 (m, 1H), 5.40-5.80 (m, 1H), 6.71-6.89 (m, 4H), 7.21-7.37 (m, 2H), 7.44 (s, 1H), 8.73 (brs, 1H), 10.11 (brs, 1H); MS (ES) m/z (relative intensity): 679 (M^+ , 100).

25

EXAMPLE 101**5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-benzyloxy-but-2-enyl)ester**

30

To a room temperature solution of 110 mg (0.25 mmol) of 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-3-oxazolidinyl)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid and 5 mL of DMF was added 69 mg (0.69 mmol) of K_2CO_3 followed by 195 mg (0.76 mmol) of

35

- 79 -

cis-4-benzyloxy-2-buten-1-methane sulfonate. After heating at 50 °C for 20 h, the reaction mixture was cooled to room temperature, poured into 50 mL of brine and extracted with 2 x 50 mL EtOAc. The combined organics were washed with 1 x 50 mL sat. aq. NaHCO₃, 1 x 50 mL brine, dried over Na₂SO₄, filtered and evaporated to a yellow oil. Flash chromatography on silica gel, eluting with CHCl₃/MeOH (40/1 to 10/1), gave 89 mg (0.12 mmol, a 47% yield) of the title compound (*R_f* = 0.30 (10/1 CHCl₃/MeOH) as a yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 0.98-1.10 (m, 3H), 2.44-2.78 (m, 3H), 2.82-3.00 (m, 2H), 4.11-4.20 (m, 4H), 4.40-4.70 (m, 2H), 4.85-4.95 (m, 4H), 5.70-5.79 (m, 2H), 5.81-5.92 (m, 2H), 6.72-6.90 (m, 3H), 7.17-7.47 (m, 14H); MS (ES) *m/z* (relative intensity): 742 (*M*⁺, 100).

EXAMPLE 102

5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid phenethyl ester

15

To a 0 °C solution of 0.630 g (1.0 mmol) of 5-((2R)-2-((2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-phenethyl) ester in 12 mL CH₃CN was added 5.6 mL 1 N NaOH (5.6 mmol), and the resulting solution was stirred at room temperature for 12 h. The solution was concentrated, 10 mL of water and 10 mL of ether were added, the pH of the mixture was adjusted to pH 8 with sat. aq. NH₄Cl, and the resulting white precipitate was collected by filtration. After washing with sat. aq. NaHCO₃, water and ether, the resulting solid was dried under vacuum to give 0.4 g (0.76 mmol, a 76% yield) of the title compound (*R_f* = 0.39; 9/1 CHCl₃/MeOH) as a tan solid; mp 75-82 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.00 (d, 3H), δ 2.5 (br m, 4H), δ 2.84-3.10 (m, 5H), δ 3.35 (br, water), δ 4.28 (t, 2H), δ 4.90 (m, 1H), δ 6.6 (d, 1H), δ 6.76 (d, 2H), δ 7.21 (br s, 6H), δ 7.36 (m, 3H), δ 7.46 (s, 1H); MS (ES) *m/z* (relative intensity): 526 (*M*⁺, 100).

- 80 -

EXAMPLE 103

5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid (1-phenyl-ethyl) ester

5 The title compound was prepared as a tan solid according to the procedure of Example 102 from 5-((2R)-2-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-phenylethyl) ester; yield: 22 %; $R_f = 0.39$ (9/1 $\text{CHCl}_3/\text{MeOH}$; mp 71-79 °C; ^1H NMR (300 MHz, DMSO-d_6): δ 1.00 (d, 3H), δ 1.5 (br m, 3H), δ 2.4-2.75 (m, 1H), δ 3.15 -3.45 (br m, 5H), δ 4.90 (br d, 1H), δ 5.20 (br d, 1H), δ 5.90 (q, 1H), δ 6.6 (d, 1H), δ 6.76 (d, 2H), δ 7.21 (br s, 6H), δ 7.36 (m, 3H), δ 7.46 (s, 1H); MS (ES) m/z (relative intensity): 526 (M^+ , 100).

EXAMPLE 104

15 **5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-benzyloxy-propyl)ester**



20 The title compound was prepared as a yellow gum from 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid and 3-benzyloxy-propanol according to the procedure of Example 1; yield: 38 %; $R_f = 0.52$ (9/1 $\text{CHCl}_3/\text{MeOH}$); ^1H NMR (300 MHz, CDCl_3): δ 1.32 (d, 3H), δ 2.00 (m, 4H), δ 2.75 (m, 1H), δ 3.30 (s, 2H), δ 3.50 (m, 4H), δ 4.40 (br m, 12H), δ 5.49 (s, 1H), δ 6.68-6.85 (m, 3H), δ 7.24-7.40 (m, 13H), δ 7.43 (s, 1H); MS (ES) m/z (relative intensity): 518 (M^+-HCl , 100).

THIS SHEET HAS BEEN
REPLACED

- 81 -


THIS SHEET HAS BEEN
REPLACED**CLAIMS****What is Claimed:**

- 1) A compound of the formula:



wherein:

- 10 R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen;
 R₂ is hydrogen or C₁ to C₆ trialkylsilyl;
 R₃ is hydrogen or C₁ to C₆ alkoxycarbonyl;
 or R₂ and R₃ are joined to form a ring:



- 15 wherein R' is hydrogen, C₁ to C₆ alkyl, or aryl;
 R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl;
 R₇ and R₈ are independently OR₉ or NR₁₀R₁₁;
 R₉ is hydrogen, C₁ to C₁₂ alkyl, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -
 20 CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision that R₉ is not hydrogen in both R₇ and R₈;
 R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, aralkyl, aryl, furanylalkyl, or alkoxycarbonylalkyl;
 R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl; or
 25 a pharmaceutically acceptable salt thereof, enantiomer thereof, racemic mixture thereof, or diastereomeric mixture thereof.

This Sheet Has Been Replaced



THIS SHEET HAS BEEN
REPLACED

- 82 -

2) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

5 3) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diphenethyl ester or a pharmaceutically acceptable salt thereof.

10 4) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-butoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

15 5) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-phenoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

20 6) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-ethoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

7) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-tert-butoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

25 8) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-tert-butoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

30 9) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isobutoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

35 10) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzyl) ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 83 -

- 11) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclohexyl) ester or a pharmaceutically acceptable salt thereof.
- 5
- 12) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclopentyl) ester or a pharmaceutically acceptable salt thereof.
- 10
- 13) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dioctyl ester or a pharmaceutically acceptable salt thereof.
- 15
- 14) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dipentyl ester or a pharmaceutically acceptable salt thereof.
- 20
- 15) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dihexyl ester or a pharmaceutically acceptable salt thereof.
- 25
- 16) A compound of Claim 1 which is carbonic acid 3-chloro-benzyl ester 2-(3-chloro-benzyloxycarbonyloxy)-4-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-phenyl ester or a pharmaceutically acceptable salt thereof.
- 30
- 17) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-phenyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 18) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diheptyl ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced.





THIS SHEET HAS BEEN
REPLACED

19) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid dinonyl ester or a pharmaceutically acceptable salt thereof.

5 20) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-decyl ester or a pharmaceutically acceptable salt thereof.

10 21) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid didodecyl ester or a pharmaceutically acceptable salt thereof.

15 22) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isopropoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

20 23) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid isopropyl ester or a pharmaceutically acceptable salt thereof.

24) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid ethyl ester or a pharmaceutically acceptable salt thereof.

25 25) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-methoxycarbonylmethyl ester or a pharmaceutically acceptable salt thereof.

30 26) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propoxycarbonylmethyl ester or a pharmaceutically acceptable salt thereof.

35 27) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methoxycarbonyl-ethyl) ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced.





THIS SHEET HAS BEEN
REPLACED

28) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropoxycarbonylmethyl ester or a pharmaceutically acceptable salt thereof.

5

29) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethoxycarbonylmethyl ester or a pharmaceutically acceptable salt thereof.

10

30) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-ethoxycarbonyl-ethyl) ester or a pharmaceutically acceptable salt thereof.

15

31) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-trimethylsilanylmethyl ester or a pharmaceutically acceptable salt thereof.

20

32) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-trimethylsilanylethyl) ester or a pharmaceutically acceptable salt thereof.

25

33) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-trimethylsilanylpropyl) ester or a pharmaceutically acceptable salt thereof.

30

34) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3,3-dimethyl-butyl) ester or a pharmaceutically acceptable salt thereof.

35) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclohexylmethyl ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 86 -

36) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-methyl-pentyl) ester or a pharmaceutically acceptable salt thereof.

5 37) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclohexyl-ethyl) ester or a pharmaceutically acceptable salt thereof.

10 38) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propyl) ester or a pharmaceutically acceptable salt thereof.

15 39) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclopropylmethyl ester or a pharmaceutically acceptable salt thereof.

20 40) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclopropyl-methyl) ester or a pharmaceutically acceptable salt thereof.

41) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclobutylmethyl ester or a pharmaceutically acceptable salt thereof.

25 42) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclopentyl-ethyl) ester or a pharmaceutically acceptable salt thereof.

30 43) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-acetoxymethyl ester or a pharmaceutically acceptable salt thereof.

35 44) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propionyloxymethyl ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 87 -

45) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-butyryloxymethyl ester or a pharmaceutically acceptable salt thereof.

5

46) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isobutyryloxymethyl ester or a pharmaceutically acceptable salt thereof.

10

47) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-heptanoyloxymethyl ester or a pharmaceutically acceptable salt thereof.

15

48) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-methyl-pentanoyloxy-methyl) ester or a pharmaceutically acceptable salt thereof.

20

49) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-hexanoyloxymethyl ester or a pharmaceutically acceptable salt thereof.

25

50) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-propionyloxymethyl) ester or a pharmaceutically acceptable salt thereof.

30

51) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis cyclohexanecarbonyloxymethyl ester or a pharmaceutically acceptable salt thereof.

52) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-propionyloxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 88 -

53) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(2,2-dimethyl-propionyloxyethyl) ester or a pharmaceutically acceptable salt thereof.

5 54) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3,3-dimethyl-butryloxy-methyl) ester or a pharmaceutically acceptable salt thereof.

10 55) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(3,3-dimethyl-butryl-oxy)ethyl)] ester or a pharmaceutically acceptable salt thereof.

15 56) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propionyl-oxy-methyl) ester or a pharmaceutically acceptable salt thereof.

20 57) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-benzoyloxymethyl ester or a pharmaceutically acceptable salt thereof.

58) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzoyloxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

25 59) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl)benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-butryloxy-methyl) ester or a pharmaceutically acceptable salt thereof.

30 60) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-amide or a pharmaceutically acceptable salt thereof.

35 61) A compound of Claim 1 which is 5-(2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-2-propyl amide or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

62) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-n-butyl amide or a pharmaceutically acceptable salt thereof.

5

63) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-phenylmethyl amide or a pharmaceutically acceptable salt thereof.

10

64) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-furanylmethyl) amide or a pharmaceutically acceptable salt thereof.

15

65) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(glycine ethyl ester) amide or a pharmaceutically acceptable salt thereof.

20

66) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-3-oxazolidinyl]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid or a pharmaceutically acceptable salt thereof.

25

67) A compound of Claim 1 which is 5-((2R)-2-{tert-Butoxycarbonyl-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-diethylcarbamoylmethyl ester or a pharmaceutically acceptable salt thereof.

30

68) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-diethyl-carbamoylmethyl ester or a pharmaceutically acceptable salt thereof.

69) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid cyclopropylmethyl ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 90 -

70) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid cyclobutylmethyl ester or a pharmaceutically acceptable salt thereof.

5 71) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis 2-(3-Thienyl)ethyl- ester or a pharmaceutically acceptable salt thereof.

10 72) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid 2-(3-Thienyl)ethyl ester or a pharmaceutically acceptable salt thereof.

15 73) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis 2-(Chloro)ethyl ester or a pharmaceutically acceptable salt thereof.

20 74) A compound of Claim 1 which is 5-{(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-ethylbutyl) ester or a pharmaceutically acceptable salt thereof.

75) A compound of Claim 1 which is 5-{(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-methylbutyl)ester or a pharmaceutically acceptable salt thereof.

25 76) A compound of Claim 1 which is 5-{(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (3-methylbutyl)ester or a pharmaceutically acceptable salt thereof.

30 77) A compound of Claim 1 which is 5-{(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-adamantan-1-ylmethyl ester or a pharmaceutically acceptable salt thereof.

35 78) A compound of Claim 1 which is 5-{(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-propyl) ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 91 -

- 79) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid adamantan-1-ylmethyl ester or a pharmaceutically acceptable salt thereof.
- 5 80) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (2,2-dimethyl-propyl)ester or a pharmaceutically acceptable salt thereof.
- 10 81) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (3,3-dimethylbutyl) ester or a pharmaceutically acceptable salt thereof.
- 82) A compound of Claim 1 which is) A compound of Claim 1 which is
15 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclohexylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 83) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-
20 (2-cyclohexyl-2-methyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 84) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-
25 (2-methyl-2-nitro-propyl) ester or a pharmaceutically acceptable salt thereof.
- 85) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-
(2,2,4-trimethyl-pentyl) ester or a pharmaceutically acceptable salt thereof.
- 30 86) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-pentyl) ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN REPLACED

- 87) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-furan-3-ylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 5 88) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-hydroxy-2,2,4-trimethyl-pentyl) ester or a pharmaceutically acceptable salt thereof.
- 10 89) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-3-phenyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 15 90) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-pyran-2-ylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 20 91) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-furan-2-ylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 25 92) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(5-methyl-[1,3]dioxan-5-ylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 30 93) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclohex-3-enylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 35 94) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-hydroxy-2,2-dimethyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 95) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-ethoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

96) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[2-(3-bromo-phenyl)-ethyl]ester hydrochloride salt.

5

97) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-m-tolyl-ethyl) ester hydrochloride salt.

10

98) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester or a pharmaceutically acceptable salt thereof.

99) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl)ester or a pharmaceutically acceptable salt thereof.

15

100) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid dicyclooctyl ester or a pharmaceutically acceptable salt thereof.

20

101) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-benzyloxy-but-2-enyl)ester or a pharmaceutically acceptable salt thereof.

25

102) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]benzo[1,3]dioxole-2,2-dicarboxylic acid phenethyl ester or a pharmaceutically acceptable salt thereof.

30

103) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]benzo[1,3]dioxole-2,2-dicarboxylic acid (1-phenyl-ethyl) ester or a pharmaceutically acceptable salt thereof.

This Sheet Has Been Replaced






THIS SHEET HAS BEEN REPLACED

104) A compound of Claim 1 which is 5-[(2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-benzyloxy-propyl)ester or a pharmaceutically acceptable salt thereof.

- 5 105) A method of treating diabetes in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of the formula:



10


wherein:

R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen;

R₂ is hydrogen or C₁ to C₆ trialkylsilyl;

15 R₃ is hydrogen or C₁ to C₆ alkoxycarbonyl;

or R₂ and R₃ are joined to form a ring:



wherein R' is hydrogen, C₁ to C₆ alkyl, or aryl;

R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl;

20 R₇ and R₈ are independently OR₉ or NR₁₀R₁₁;

R₉ is hydrogen, C₁ to C₁₂ alkyl, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision that R₉ is not hydrogen in both R₇ and R₈;

25 R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, aralkyl, aryl, furanylalkyl, or alkoxycarbonylalkyl;

R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl; or a pharmaceutically acceptable salt thereof, enantiomer thereof, racemic mixture thereof, or diastereomeric mixture thereof.


This Sheet Has Been Replaced






106) A method of treating obesity in a mammal, the method comprising administering to a mammal in need thereof an effective amount of compound of the formula:

5



wherein:


- 10 R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen;
 R₂ is hydrogen or C₁ to C₆ trialkylsilyl;
 R₃ is hydrogen or C₁ to C₆ alkoxycarbonyl;
 or R₂ and R₃ are joined to form a ring:



- 15 wherein R' is hydrogen, C₁ to C₆ alkyl, or aryl;
 R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl;
 R₇ and R₈ are independently OR₉ or NR₁₀R₁₁;
 R₉ is hydrogen, C₁ to C₁₂ alkyl, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -
 20 CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision that R₉ is not hydrogen in both R₇ and R₈;
 R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, aralkyl, aryl, furanylalkyl, or alkoxycarbonylalkyl;
 R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl; or
 25 a pharmaceutically acceptable salt thereof, enantiomer thereof, racemic mixture thereof, or diastereomeric mixture thereof.



107) A method of treating hyperglycemia in a mammal, the method comprising administering to a mammal in need thereof an effective amount of compound of the formula:



5

wherein:


R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen;

10

R₂ is hydrogen or C₁ to C₆ trialkylsilyl;

R₃ is hydrogen or C₁ to C₆ alkoxycarbonyl;

or R₂ and R₃ are joined to form a ring:



wherein R' is hydrogen, C₁ to C₆ alkyl, or aryl;

15

R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl;

R₇ and R₈ are independently OR₉ or NR₁₀R₁₁;

R₉ is hydrogen, C₁ to C₁₂ alkyl, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision that R₉ is not hydrogen in both R₇ and R₈;

20


R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, aralkyl, aryl, furanylalkyl, or alkoxycarbonylalkyl;

R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl; or a pharmaceutically acceptable salt thereof, enantiomer thereof, racemic mixture thereof, or diastereomeric mixture thereof.

25




108) A pharmaceutical composition comprising an effective amount of a compound of the formula:



wherein:

- 5 R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen;
 R₂ is hydrogen or C₁ to C₆ trialkylsilyl;
 R₃ is hydrogen or C₁ to C₆ alkoxycarbonyl;
 or R₂ and R₃ are joined to form a ring:




10

wherein R' is hydrogen, C₁ to C₆ alkyl, or aryl;

- R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl;
 R₇ and R₈ are independently OR₉ or NR₁₀R₁₁;
 R₉ is hydrogen, C₁ to C₁₂ alkyl, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl,
 15 aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -
 CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision
 that R₉ is not hydrogen in both R₇ and R₈;
 R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, aralkyl, aryl,
 furanylalkyl, or alkoxycarbonylalkyl;
 20 R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl; or
 a pharmaceutically acceptable salt thereof, enantiomer thereof, racemic mixture thereof,
 or diastereomeric mixture thereof, in combination with a pharmaceutically acceptable
 carrier.

- 25 109) A process for preparing a compound of formula II as claimed in Claim 1 which
 comprises one of the following:

a) reacting a compound of formula:



wherein $R_2 - R_6$ are as defined in Claim 1 OH and R_8 is OAg or R_8 as defined above excepting OH with a compound of formula:

5




wherein R_{12} and R_{13} are as defined in Claim 1 to give a compound of formula II wherein R_9 is

10



b) reacting a compound of formula:




15

wherein $R_1 - R_6$ and R_8 are as defined above with compound of formula R_9OH where R_9 is as defined above excepting hydrogen to give a corresponding compound of formula II; or

20

c) hydrolysing a compound for formula:






wherein R_1 , R_4 , R_5 , R_6 , R_7 and R_8 are as defined in Claim 1 and R_2 is trialkylsilyl and R_3 is $(C_1-C_6 \text{ alkoxy})$ -carbonyl to give a corresponding compound of formula 1 wherein R_2 and R_3 are both hydrogen; or


- 5 d) reacting a compound of formula I wherein R_2 and R_3 are both hydrogen with an aldehyde of formula:



- 10 wherein R' is as defined in Claim 1 to give a corresponding compound of formula II wherein R_2 and R_3 are joined to form a ring:



- 15 e) reacting a compound of formula:




- 20 wherein R_1 , R_4 , R_5 and R_8 are as defined in Claim 1 with the proviso neither R_2 or R_3 is hydrogen with a compound of formula:




- 25 wherein Z is Cl , Br , I , methanesulfonate or p -toluenesulfonate and R_9 is as defined in Claim 1 excepting hydrogen, to give a corresponding compound of formula II; or

- f) hydrolysing a compound of formula:


- 100 -



- 5 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in Claim 1, R₈ is OR₉' or NR₁₀R₁₁ and R₉' is C₁-C₁₂ alkyl, C₁-C₁₂ cycloalkyl, C₁-C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl or heteroaryl to give a compound of formula:




- 10 wherein R₁-R₆ and R₈ are as defined above providing that R₂ and R₃ are both hydrogen or joined to form a ring:



; or

- 15 g) reacting a compound of formula:




- 20 wherein R₁-R₆ and R₈ are as defined in Claim 1 and R₉' as defined above, with a compound of formula:

- 101 -


 $\text{HNR}_{11}\text{R}_{12}$

wherein R_{11} and R_{12} are as defined in Claim 1 to give a compound of formula:




5

wherein R_1 - R_6 , R_8 , R_{11} and R_{12} are as defined in Claim 1.

**CLAIMS**

- 1) A compound of the formula:




wherein:

R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen;

R₂ is hydrogen or C₁ to C₆ trialkylsilyl;

R₃ is hydrogen or C₁ to C₆ alkoxycarbonyl;

or R₂ and R₃ are joined to form a ring:



wherein R' is hydrogen, C₁ to C₆ alkyl, or aryl;


R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl;

R₇ and R₈ are independently OR₉;

R₉ in each instance is independently selected from hydrogen, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision that R₉ is not hydrogen in both R₇ and R₈;

R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, aralkyl, aryl, furanylalkyl, or alkoxycarbonylalkyl;

R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl; or a pharmaceutically acceptable salt thereof, enantiomer thereof, racemic mixture thereof, or diastereomeric mixture thereof.



-82-

REPLACEMENT SHEET



- 2) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 3) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid diphenethyl ester or a pharmaceutically acceptable salt thereof.
- 4) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-butoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 5) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-phenoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 6) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-ethoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 7) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-tert-butoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 8) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-tert-butoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 9) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isobutoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 10) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzyl) ester or a pharmaceutically acceptable salt thereof.

11 NOV 1999




- 11) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclohexyl) ester or a pharmaceutically acceptable salt thereof.
- 12) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(cyclopentyl) ester or a pharmaceutically acceptable salt thereof.
- 13) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-phenyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 14) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-isopropoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 15) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-methoxycarbonylmethyl ester or a pharmaceutically acceptable salt thereof.
- 16) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propoxycarbonylmethyl ester or a pharmaceutically acceptable salt thereof.
- 17) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methoxycarbonyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 18) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isopropoxycarbonyl-methyl ester or a pharmaceutically acceptable salt thereof.
- 19) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-ethoxycarbonylmethyl ester or a pharmaceutically acceptable salt thereof.

11 NOV 1999



- 20) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-ethoxycarbonyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 21) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-trimethylsilanylmethyl ester or a pharmaceutically acceptable salt thereof.
- 22) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-trimethylsilyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 23) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-trimethylsilyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 24) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclohexylmethyl ester or a pharmaceutically acceptable salt thereof.
- 25) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclohexyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 26) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 27) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclopropylmethyl ester or a pharmaceutically acceptable salt thereof.
- 28) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclopropyl-methyl) ester or a pharmaceutically acceptable salt thereof.




-85-

REPLACEMENT SHEET



- 29) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-cyclobutylmethyl ester or a pharmaceutically acceptable salt thereof.
- 30) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclopentyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 31) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-acetoxymethyl ester or a pharmaceutically acceptable salt thereof.
- 32) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-propionyloxymethyl ester or a pharmaceutically acceptable salt thereof.
- 33) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-butyryloxymethyl ester or a pharmaceutically acceptable salt thereof.
- 34) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-isobutyryloxymethyl ester or a pharmaceutically acceptable salt thereof.
- 35) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-heptanoyloxymethyl ester or a pharmaceutically acceptable salt thereof.
- 36) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-methyl-pentanoyloxy-methyl) ester or a pharmaceutically acceptable salt thereof.
- 37) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-hexanoyloxymethyl ester or a pharmaceutically acceptable salt thereof.




-86-



REPLACEMENT SHEET




- 38) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-propionyloxymethyl) ester or a pharmaceutically acceptable salt thereof.
- 39) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis cyclohexanecarbonyl-oxymethyl ester or a pharmaceutically acceptable salt thereof.
- 40) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-propionyloxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 41) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(2,2-dimethyl-propionyloxyethyl) ester or a pharmaceutically acceptable salt thereof.
- 42) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3,3-dimethyl-butyryloxy-methyl) ester or a pharmaceutically acceptable salt thereof.
- 43) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[1-(3,3-dimethyl-butyryl-oxy)ethyl)) ester or a pharmaceutically acceptable salt thereof.
- 44) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-cyclopentyl-propionyl-oxymethyl) ester or a pharmaceutically acceptable salt thereof.
- 45) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-benzoyloxymethyl ester or a pharmaceutically acceptable salt thereof.
- 46) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(benzoyloxy-ethyl) ester or a pharmaceutically acceptable salt thereof.



- 47) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-2-hydroxy-ethylamino]propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-butyryloxy-methyl) ester or a pharmaceutically acceptable salt thereof.
- 48) A compound of Claim 1 which is 5-{2-[2-(3-chloro-phenyl)-3-oxazolidinyl]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid or a pharmaceutically acceptable salt thereof.
- 49) A compound of Claim 1 which is 5-((2R)-2-{tert-Butoxycarbonyl-[(2R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-diethylcarbamoylmethyl ester or a pharmaceutically acceptable salt thereof.
- 50) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-diethyl-carbamoylmethyl ester or a pharmaceutically acceptable salt thereof.
- 51) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid cyclopropylmethyl ester or a pharmaceutically acceptable salt thereof.
- 52) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid cyclobutylmethyl ester or a pharmaceutically acceptable salt thereof.
- 53) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis 2-(3-Thienyl)ethyl- ester or a pharmaceutically acceptable salt thereof.
- 54) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid 2-(3-Thienyl)ethyl ester or a pharmaceutically acceptable salt thereof.
- 55) A compound of Claim 1 which is 5-{2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-benzo[1,3]dioxole-2,2-dicarboxylic acid bis 2-(Chloro)ethyl ester or a pharmaceutically acceptable salt thereof.




- 56) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-adamantan-1-ylmethyl ester or a pharmaceutically acceptable salt thereof.
- 57) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid adamantan-1-ylmethyl ester or a pharmaceutically acceptable salt thereof.
- 58) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclohexylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 59) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-cyclohexyl-2-methyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 60) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-methyl-2-nitro-propyl) ester or a pharmaceutically acceptable salt thereof.
- 61) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-furan-3-ylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 62) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-hydroxy-2,2,4-trimethyl-pentyl) ester or a pharmaceutically acceptable salt thereof.
- 63) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2,2-dimethyl-3-phenyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 64) A compound of Claim 1 which is 5-((2R)-2-((2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-pyran-2-ylmethyl) ester or a pharmaceutically acceptable salt thereof.



-89-

REPLACEMENT SHEET

- 65) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(tetrahydro-furan-2-ylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 66) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(5-methyl-[1,3]dioxan-5-ylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 67) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(1-methyl-cyclohex-3-enylmethyl) ester or a pharmaceutically acceptable salt thereof.
- 68) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-hydroxy-2,2-dimethyl-propyl) ester or a pharmaceutically acceptable salt thereof.
- 69) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (2-ethoxy-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 70) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-[2-(3-bromo-phenyl)-ethyl]ester hydrochloride salt.
- 71) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(2-m-tolyl-ethyl) ester hydrochloride salt.
- 72) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid diallyl ester or a pharmaceutically acceptable salt thereof.
- 73) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-phenyl-allyl)ester or a pharmaceutically acceptable salt thereof.




- 74) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid dicyclooctyl ester or a pharmaceutically acceptable salt thereof.
- 75) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(4-benzyloxy-but-2-enyl)ester or a pharmaceutically acceptable salt thereof.
- 76) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid phenethyl ester or a pharmaceutically acceptable salt thereof.
- 77) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid (1-phenyl-ethyl) ester or a pharmaceutically acceptable salt thereof.
- 78) A compound of Claim 1 which is 5-((2R)-2-[(2R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl)-benzo[1,3]dioxole-2,2-dicarboxylic acid bis-(3-benzyloxy-propyl)ester or a pharmaceutically acceptable salt thereof.
- 79) Use of a compound as claimed in any one of claims 1 to 78 in the preparation of a medicament for treating diabetes in a mammal,
- 80) Use of a compound as claimed in any one of claims 1 to 78 in the preparation of a medicament for treating obesity in a mammal.
- 81) Use of a compound as claimed in any one of claims 1 to 78 in the preparation of a medicament for treating hyperglycemia in a mammal.
- 82) A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, enantiomer thereof, racemic mixture thereof, or diastereomeric mixture thereof, in combination with a pharmaceutically acceptable carrier.



83) A process for preparing a compound as claimed in Claim 1 which comprises one of the following:

a) reacting a compound of formula:




wherein $R_1 - R_6$ are as defined in Claim 1 OH and R_8' is OAg or R_8 as defined above excepting OH with a compound of formula:



wherein R_{12} and R_{13} are as defined in Claim 1 to give a compound of formula II wherein R_9 is




b) reacting a compound of formula:



wherein $R_1 - R_6$ and R_8 are as defined above with compound of formula R_9OH where R_9 is as defined above excepting hydrogen to give a corresponding compound of formula II; or

c) hydrolysing a compound for formula:




wherein R₁, R₄, R₅, R₆, R₇ and R₈ are as defined in Claim 1 and R₂ is trialkylsilyl and R₃ is (C₁-C₆ alkoxy)-carbonyl to give a corresponding compound of formula 1 wherein R₂ and R₃ are both hydrogen; or


d) reacting a compound of formula I wherein R₂ and R₃ are both hydrogen with an aldehyde of formula:



wherein R' is as defined in Claim 1 to give a corresponding compound of formula II wherein R₂ and R₃ are joined to form a ring:



e) reacting a compound of formula:




wherein R₁, R₄, R₅ and R₈ are as defined in Claim 1 with the proviso neither R₂ or R₃ is hydrogen with a compound of formula:




wherein Z is Cl, Br, I, methanesulfonate or p-toluenesulfonate and R₉ is as defined in Claim 1 excepting hydrogen, to give a corresponding compound of formula II; or




f) hydrolysing a compound of formula:




wherein R_1 , R_2 , R_3 , R_4 , R_5 and R_6 are as defined in Claim 1, R_8 is $OR_{9'}$ or and $R_{9'}$ is C1-C12 alkyl, C1-C12 cycloalkyl, C1-C12 silylalkyl, aryl, arylalkyl, alkoxyalkyl or heteroaryl to give a compound of formula:



wherein R_1 - R_6 and R_8 are as defined above providing that R_2 and R_3 are both hydrogen or joined to form a ring:




g) reacting a compound of formula:



wherein R_1 - R_6 and R_8 are as defined in Claim 1 and $R_{9'}$ as defined above, with a compound of formula:



wherein R_{11} and R_{12} are as defined in Claim 1 to give a compound of formula:



wherein R_1 - R_6 , R_{11} and R_{12} are as defined in claim 1



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:

C07D 317/46, 413/06, A61K 31/42

A1

(11) International Publication Number:

WO 97/43273

(43) International Publication Date: 20 November 1997 (20.11.97)

(21) International Application Number:

PCT/US97/08148

(22) International Filing Date:

9 May 1997 (09.05.97)

(30) Priority Data:

08/645,970

14 May 1996 (14.05.96)

US

(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: GILBERT, Adam, Matthew; 770 Sierra Vista Lane, Valley Cottage, NY 10989 (US); GROSU, George, Theodore; 117 Prospect Place, Pearl River, NY 10965 (US); MALAMAS, Michael, Sotirios; 2443 Oleander Circle, Jamison, PA 18929 (US); SUM, Fuk-Wah; 16 Chamberlain Court, Pomona, NY 10970 (US); VENKATESAN, Arana-pakam, Mudumbai; Apartment 9K, 97-07 63rd Road, Rego Park, NY 11374 (US); FRANCISCO, Gerardo De la Cruz; 23 Henry Street, Orangeburg, NY 10962 (US).

Published

With international search report.


Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.


(54) Title: SUBSTITUTED 1, 3-BENZODIOXOLES

(57) Abstract

The present invention provides new compounds having anti-diabetic and/or antihyperglycemia and/or anti-obesity activity, as well as pharmaceutical compositions and methods of treatment utilizing the compounds and processes for making the compounds, the compounds having formula (II), wherein: R₁ and R₆ are independently hydrogen, C₁ to C₆ alkyl, trifluoromethyl, cyano, C₁ to C₆ alkoxy, or halogen; R₂ is hydrogen or C₁ to C₆ trialkylsilyl; R₃ is hydrogen or C₁ to C₆ alkoxy-carbonyl; or R₂ and R₃ are joined to form a ring (a): wherein R' is hydrogen, C₁ to C₆ alkyl or aryl; R₄ and R₅ are independently hydrogen or C₁ to C₆ alkyl; R₇ and R₈ are independently OR₉ or NR₁₀R₁₁; R₉ is hydrogen, C₁ to C₁₂ alkyl, C₁ to C₁₂ cycloalkyl, C₁ to C₁₂ silylalkyl, aryl, arylalkyl, alkoxyalkyl, heteroaryl, -CHR₁₂COOR₁₃, -CHR₁₂C(O)R₁₃, -CHR₁₂CONR₁₀R₁₁, -CHR₁₂OCOOR₁₃, or -CHR₁₂OC(O)R₁₃, with the provision that R₉ is not hydrogen in both R₇ and R₈; R₁₀ and R₁₁ are independently hydrogen, C₁ to C₁₂ alkyl, aralkyl, aryl, furanylalkyl, or alkoxy-carbonylalkyl; R₁₂ and R₁₃ are independently hydrogen, C₁ to C₁₂ alkyl, aryl, or aralkyl; and their pharmaceutically acceptable salts thereof, the enantiomers thereof, the racemic mixtures thereof, and the diastereomeric mixtures thereof.



(II)



(a)